



EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en PATENTSCOPE sobre vacunas.
- Patentes más recientes en USPTO sobre vacunas.

Noticias en la Web

Sanofi's Chinese Pediatric Meningococcal Vaccine Trial Advances, Sharpening Long-Term Growth Prospects for SNY

Sep 23. Sanofi (SNY) is running a Phase 3 trial in China to test an investigational four strain meningococcal vaccine in babies and toddlers. The study, officially titled “A Phase 3, Modified-double Blind, Multi-center Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine... in China,” aims to show strong protection and good safety versus local options, which could support broader use in a key growth market.



The main treatment is MenQuadfi, a conjugate vaccine designed to protect against four meningococcal strains A, C, W and Y. It is given as muscle injections and is tested head to head against CanSino Biologics' Menhycia, a locally approved vaccine, to see if Sanofi can match or beat current standards in young children.

The trial is interventional and randomized, so children are assigned by chance to either Sanofi's or CanSino's vaccine. Most groups are double blind with four way masking, which means families, doctors, study staff and outcome assessors do not know which vaccine is given, and the main goal is to prevent disease rather than treat existing illness.

The study uses parallel groups, so several age bands and dosing schedules run at the same time instead of sequentially. One group in the youngest cohort is open label, which simplifies operations for that arm but should not affect the broader safety and immune response readout that investors will watch.

Key timing signals matter for investors even before results. The trial was first submitted July 13, 2026, with recruiting status now active, and the latest update was posted September 20, 2026, showing the study is moving forward and confirming Sanofi's commitment to the Chinese pediatric vaccine market.

Primary and final completion dates will likely fall several years after first dosing, because safety follow up runs up to 21 months in some cohorts. As these milestones approach, traders will price in data risk and potential approvals in China, which could add a new revenue stream to Sanofi's vaccine franchise.

For Sanofi, solid Phase 3 data could strengthen its global meningococcal portfolio and support higher penetration in emerging markets. Success may also soften reliance on older products, improve long term growth visibility and support valuation multiples for SNY if investors gain confidence in the vaccine pipeline.

The comparator, Menhycia from CanSino Biologics, highlights intense local competition for infant and toddler shots. If MenQuadfi shows equal or better performance, Sanofi could win share at the expense of local rivals, while weaker results could instead lift sentiment for domestic players and limit upside for SNY in China.

In the near term, the update mainly signals execution rather than a direct revenue shift, so stock moves may be modest and tied to broader sector trends. But as the study advances and interim signals emerge,

news flow around safety or immune response could drive trading swings in vaccine names across the global and Chinese markets.

The trial remains active and updated, and investors can track ongoing protocol changes and timelines on the ClinicalTrials portal for more detailed information.

Fuente: The Globe and Mail. Disponible en <https://n9.cl/b165ir>

Singapore to support mRNA flu vaccine pilot to strengthen pandemic preparedness

Sep 24. Singapore plans to support the mRNA influenza vaccine pilot initiative in the country, Health Minister Ong Ye Kung said on Wednesday (Sep 23).

Speaking at the United Nations General Assembly side event on Outbreak Preparedness and Response in New York, Mr Ong said the initiative would serve a "peacetime need", while helping Singapore build up adaptable capabilities.

He added that he hoped Hilleman Laboratories could support the effort.

Hilleman, a vaccine research organisation, officially opened its US\$20 million vaccine manufacturing facility in Singapore in 2023.

Mr Ong said that Singapore is also working with companies such as Sanofi, GSK, Moderna and Thermo Fisher Scientific, which have capabilities across vaccine platforms and manufacturing.

He noted that in a crisis, even a country's best plans and investments may not yield the most effective vaccine.

"In fact I would say, most are not likely to. It may be discovered and developed by any of the many research teams around the world," Mr Ong said.

Therefore, vaccine production facilities must be able to secure a licence, receive technology transfer and adapt their production lines quickly.

Such facilities must remain "warm" in peacetime by producing needed vaccines and maintaining operational readiness, Mr Ong said. "You cannot simply turn on a dormant factory during an emergency and expect it to run smoothly," he added, noting that "preparedness is a living capability".

POSSIBLE BUNDIBUGYO EBOLA VACCINE

Mr Ong also announced that Hilleman's Singapore facility is adapting manufacturing know-how from MSD's Zaire Ebola virus vaccine, ERVEBO, to accelerate the Bundibugyo vaccine candidate alongside support from the Coalition for Epidemic Preparedness Innovations (CEPI).

There are currently no approved vaccines or drugs for the Bundibugyo Ebola virus.

The facility will produce material for early clinical trials, with the first batch available by the end of this year.

Mr Ong said that Hilleman's production capacity could produce a drug substance equivalent to 50 to 60 million doses, or 12 million doses of drug product annually for this vaccine.



Depending on needs, Hilleman could also make arrangements for the transfer of technology to a larger-scale manufacturer in the region.

Mr Ong said that this showed "preparedness in action".

"Existing science, an operating facility that is kept warm, and trusted partners to scale up – all of which shorten the path from threat to a full response," he added.

"It offers us a possible approach in response to Disease X in future."

Disease X is the name given to an unknown pathogen that could emerge in future and cause a serious international epidemic or pandemic, according to CEPI.

"FOCUSED CONTRIBUTION"

Should regional efforts stall during an emergency, Singapore could make a "focused contribution" together with its partners, Mr Ong said.

He outlined several areas, one being a vigilant global surveillance system that detects dangerous pathogens early, which rests on platforms where scientists and governments are willing to share data willingly and quickly.

Singapore already works closely with GISAID, a leading international repository of genomic data for SARS-CoV-2, mpox and influenza viruses.

Mr Ong highlighted how Singapore's National Public Health Laboratory, in late July, detected a recombinant form of SARS-CoV-2, the coronavirus that causes COVID-19, through routine genomic surveillance.

At the time of assessment, it was the only such sequence detected in Singapore, with no closely matching sequence identified in GISAID's database.

Mr Ong noted that the patient had mild illness and recovered, and no further local cases were detected, while the sequence was submitted on the GISAID platform for global analysis.

"A country that reports an unusual pathogen may worry ... about reputational or economic consequences," said the minister.

"The answer is not to delay reporting, but to build international norms that recognise transparency as responsible conduct."

Mr Ong also called for support for CEPI's 100-day mission, noting that it has made significant progress towards developing safe, effective and accessible vaccines for initial authorisation and manufacturing at scale within 100 days of identifying a pandemic threat.

"The strategy is to do as much work as possible before the crisis, by building prototype vaccine libraries for representative viruses, validating adaptable platforms, and preparing laboratories, clinical-trial networks, manufacturers and regulators to move in concert."

Singapore is aligning its vaccine development efforts under its Prepvax research initiative with CEPI's mission, Mr Ong said. PrepVax is a national programme established by the Ministry of Health to organise vaccine development capabilities across Singapore's public and private institutions.

Lastly, vaccines must be evaluated, approved and deployed quickly without compromising safety and quality.

Trust built in peacetime allows authorities to rely on one another's assessments, share workloads and reduce duplication, because during a crisis, regulators tend to operate with "urgency and incomplete information", Mr Ong noted.

The nature of Disease X is likely be novel, deadly and fast-spreading, but the minister said mRNA could offer the greatest flexibility in development and time to market, which is why Singapore plans to support the mRNA influenza vaccine pilot initiative

"To prepare for Disease X, we must resist denial, stigma, unfairness and the temptation to retreat behind national borders when global co-operation is most needed," he added.

"We need to cooperate with each other, place our confidence in science and put in place overlapping and complementary plans ahead of time.

"The next outbreak will not wait for us to smoothen every kink and settle every disagreement. Preparedness must therefore be built now - patiently, practically and together."

Fuente: CNA Channel News Asia. Disponible en <https://n9.cl/o0lla>

Connecting Innovation and Global Markets: Jeanne Wang on CanSinoBIO's Next Stage of Growth

Sep 24. Five years ago, Jeanne Wang transitioned from Chief Financial Officer to Chief Commercial Officer at CanSino Biologics (CanSinoBIO), a pioneering Chinese biotechnology company focused on vaccine innovation, following the company's listings in Hong Kong and Shanghai. Over the past five years, she has played a leading role in shaping the company's evolution from an R&D-focused biotech into a business with a growing commercial portfolio and an increasingly international footprint.



That evolution is becoming increasingly visible in CanSinoBIO's financial and commercial performance. In the first half of 2026, the company reported revenue of RMB550 million, up 43.8% year on year, while overseas revenue reached RMB152 million.

For Jeanne Wang, the growth is not an overnight development, but the result of years of investment and preparation. "It is not a surprise," she said. "It reflects the direction we have been committed to for years."


Having been with CanSinoBIO for 15 years, Jeanne Wang has been part of its transformation from early-stage vaccine research and fundraising to public listings, scaled manufacturing, commercialization and international expansion. Looking ahead, she sees the company's next stage as one defined by closer integration between innovation and the market.

She believes commercialization is about creating stronger connections between innovation, products and market needs. As CanSinoBIO advances its commercialization efforts, this approach is increasingly reflected in the expansion of its product portfolio.

Its quadrivalent meningococcal conjugate vaccine (MCV4) continues to contribute commercial revenue, while its 13-valent pneumococcal conjugate vaccine (PCV13i) has advanced in both domestic and

overseas markets. The company is also extending its pertussis portfolio across different age groups. Its three-component diphtheria, tetanus and acellular pertussis vaccine (DT3cP) has been approved in China for infants, while its New Drug Application (NDA) for a five-component product (Td5cp) targeting adolescents and adults was accepted by China's NMPA for review in August.

Meanwhile, the company has expanded the indicated age range of MCV4 and received approval for its adsorbed tetanus vaccine, adding further depth to its portfolio. For CanSinoBIO, however, expanding the portfolio is not simply about adding more products. The company is also seeking to leverage its five core technology platforms across different vaccine programs. Its DT3cP-Hib-MCV4 combination vaccine and recombinant polio vaccine currently under clinical development illustrate this approach.



The broader objective is to move from individual products toward greater platform synergies — from single vaccines to combination and multivalent products, and from pediatric immunization to a broader life-course portfolio.

This transformation is taking place alongside another major shift: the company's internationalization. Chinese vaccine makers have accelerated their efforts to enter overseas markets in recent years, but international expansion involves more than securing regulatory approval and supplying products. Companies must navigate differences in disease burden, regulatory systems, immunization policies, healthcare financing, supply chains, manufacturing capabilities and commercial channels.

CanSinoBIO is therefore seeking to integrate domestic and overseas operations rather than treating international business as a separate track. The development of PCV13i in Indonesia offers an example. As one of Southeast Asia's largest markets, Indonesia is expanding its capacity to meet growing immunization needs through domestic investment and procurement. CanSinoBIO has supplied the product for its PCV13i vaccine to the Indonesian partner, supporting subsequent local manufacturing and potential supply to the national immunization program.

For Jeanne Wang, the experience highlights an important principle for Chinese vaccine companies going global: there is no single model that works across markets. "The starting point is always the local needs," she said, referring to factors including disease burden, regulatory requirements, immunization policies and market demand. Products and partnership models need to match those conditions.

In some emerging markets, she has observed that the interest of local partners goes beyond individual products. They are increasingly interested in technology platforms and in developing innovative vaccines through clinical studies involving local populations, to achieve regulatory approval in their own markets alongside other countries.

This points to a broader shift in the internationalization of Chinese vaccine companies — from exporting products to expanding technology, clinical development and industrial capabilities overseas.

For CanSinoBIO, that represents an extension of its commercialization strategy rather than a separate path outside the domestic business. The company is seeking to build a portfolio that can address different stages of the life course while developing partnerships that connect its technologies and products with local healthcare needs.

Jeanne Wang also sees opportunities for greater collaboration among China's innovative biopharmaceutical companies as they expand internationally. In her view, if companies can build more effective cooperation around real market and public health needs — from products and technologies to supply chains and local partnerships — Chinese innovators could enter global markets in a more efficient and sustainable way.

For Jeanne Wang, the next phase is therefore more about finding ways for innovation to create value across different healthcare systems. After 15 years at CanSinoBIO, her perspective reflects not only the company's shift from R&D toward commercialization, but also a broader question facing China's innovative biopharmaceutical sector: how to connect domestic innovation more effectively with healthcare needs around the world.

Fuente: YICAI GLOBAL. Disponible en <https://n9.cl/007eu>

2 studies find strong RSV vaccine protection against severe outcomes in older adults

Sep 25. The bivalent (two-strain) respiratory syncytial virus (RSV) vaccine made by Pfizer (RSVpreF, or Abrysvo) reduced the risk of hospitalization and emergency department (ED) visits for at least three seasons after vaccination in older adults with a high prevalence of comorbidities, according to a study published last week in *Infectious Diseases and Therapy*.

A separate study published the same day in *JAMA Network Open* found that RSV vaccines provided substantial protection against RSV-related hospitalization and death among adults

aged 65 and older and people with weakened immune systems during the 2023-24 respiratory virus season.

RSV is a leading cause of lower respiratory tract disease (LRTD) with severe outcomes, particularly among older adults and those with compromised immune systems. The Centers for Disease Control and Prevention estimates that RSV contributes to around 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths among older adults in the United States each year.

Protection may persist into third season

For the study that looked at RSV vaccine protection over the course of three seasons, researchers led by a team from Kaiser Permanente Southern California and Pfizer analyzed data from 3,131 hospital and ED visits for LRTD and 4,797 for acute respiratory illness (ARI) among adults aged 60 and older. Roughly 71% of the LRTD visits and 57% of the ARI visits resulted in hospitalization.



After adjusting for differences between the groups, the researchers estimated that vaccination was 80% effective against RSV-related LRTD requiring hospitalization or ED care in the first season after vaccination and 70% in the second. The estimate fell to 51% in the third season, but the 95% confidence interval (CI) was wide due to a limited number of events and ranged as low as -12%, meaning the study couldn't establish protection against hospitalization or ED care in year three.

The RSV vaccine's estimated effectiveness against ARI-related hospitalization and ED care was 81% in the first year, 64% in the second year, and 60% (95% CI, 15% to 81%) in the third year. The confidence interval for third-season ARI vaccination effectiveness was slightly narrower and stayed above zero, suggesting that the vaccine offered protection in the third year.

"Additional studies and analyses are needed to further define durability of protection in specific population subgroups," write the researchers.

But overall, they conclude, "Bivalent RSVpreF provides protection against RSV-related respiratory disease hospitalization/ED visits for at least three seasons after vaccination, resulting in substantial individual and public health benefit."

Vaccines cut hospitalization rates by 82%

For the study that estimated vaccine effectiveness (VE) during the 2023-24 respiratory virus season, researchers from the Food and Drug Administration analyzed data from more than 14.5 million US adults aged 65 years and older to assess the how well both the RSVPreF3+AS01 (an adjuvanted vaccine, Arexvy, made by GSK) and RSVpreF protected against hospitalization and death.

Among the participants, the median age was 74 years, and roughly 58% were women. Approximately 14% received RSVPreF3+AS01, and around 6% received an RSVpreF vaccine.

Overall, the researchers estimated that VE against RSV-related hospitalization was nearly 82% and was 85% against RSV death. For immunocompromised participants, VE against RSV hospitalization was approximately 72%.

“RSV vaccines provided substantial protection to immunocompromised people.”

"The large study size allowed us to granularly assess risk against RSV-related hospitalization by age, finding no evidence of effect modification by age, including for beneficiaries aged 85 years or older," write the researchers. "The large study size also allowed us to assess effectiveness by more granular immunocompromised subcategories. RSV vaccines provided substantial protection to immunocompromised individuals."

The authors conclude that "the RSVPreF3+AS01 and RSVpreF RSV vaccines had high estimated effectiveness against RSV-related hospitalization and death" in adults aged 65 and older, including immunocompromised people.

Fuente: CIDRAP. Disponible en <https://n9.cl/9rmqv>

WHO Recommends 2027 Southern Hemisphere Flu Vaccine Composition

Sep 26. The World Health Organization (WHO) has announced its recommendations for the viral composition of influenza vaccines to be used during the 2027 Southern Hemisphere influenza season, following an international consultation involving experts from WHO Collaborating Centres and Essential Regulatory Laboratories.

The recommendations are based on global influenza surveillance data collected through the Global Influenza Surveillance and Response System (GISRS) and other sources. WHO updates influenza vaccine composition twice a year because circulating influenza viruses continually evolve, requiring vaccines to be adjusted to maintain protection against the strains expected to cause disease.

From February to August 2026, influenza A(H1N1)pdm09, A(H3N2), and influenza B viruses circulated across regions worldwide. Influenza A viruses were predominant in most regions, while influenza B viruses dominated in Northern and Western Africa, North America, and Eastern Asia.

For the 2027 Southern Hemisphere season, WHO has recommended vaccine compositions targeting A(H1N1)pdm09, A(H3N2), and B/Victoria lineage viruses. The specific recommended strains vary depending on whether vaccines are produced using egg-based or cell culture-, recombinant protein-, or nucleic acid-based technologies.

WHO also assessed influenza viruses circulating in animals, particularly zoonotic viruses that have infected humans. These viruses remain an important area of pandemic preparedness because of their potential to develop into viruses capable of sustained human transmission.

The biannual review also supports the selection of candidate vaccine viruses (CVVs) from contemporary zoonotic influenza viruses, which could help accelerate vaccine development and production if a pandemic influenza threat emerges.



Fuente: VOICE OF HEALTH. Disponible en <https://n9.cl/fkprk>

Europe Injects Capital into Colombian Biotech Firm to Produce 250 Million Vaccines

Sep 26. The European Investment Bank (EIB), in collaboration with the European Commission, the politically independent executive body of the European Union responsible for proposing legislation, implementing policies and managing the EU budget, will grant a 15 million euro (US\$17 million) venture debt loan to a Colombian biotechnology company dedicated to the development, manufacture and commercialization of vaccines and biopharmaceutical products.

This type of loan is financing in which a startup or high-growth company receives credit from a financial institution or specialized fund, without the need to give up a large portion of its shares.

Unlike traditional bank loans, it does not require

a long history of profits or strong physical collateral; instead, it is granted to companies that already have the backing of venture capital funds.

250 million doses annually and aid to Latin America

The beneficiary is VaxThera, and the agreement, announced in New York within the framework of the 81st United Nations General Assembly, constitutes the first tranche of an already approved financing package of 35 million euros (US\$39.8 million).


This financing will be used for the construction, fitting-out and validation of the second phase of the company's large-scale integrated plant for the production of vaccines and biological medicines.

It will allow VaxThera to manufacture up to 250 million annual doses of liquid and lyophilized biological products (between 600 and 700 million doses in the event of a pandemic), those involved said in a joint press release signed by Global Gateway (the European Union's strategy for making sustainable investments in quality infrastructure worldwide), the European Union, the EIB and the beneficiary company.

The boost is for processes that cover the entire vaccine manufacturing cycle, including upstream processing and precision filling. This means that the Colombian biotechnology company will be able to manufacture its own vaccines, subject to regulatory authorization, and provide development and contract manufacturing services for other biological products.

It will also support technology transfer and research and development (R&D) activities in order to address important unmet medical needs.

"This investment will strengthen Colombia's vaccine research and manufacturing capacity, as it will allow VaxThera to produce up to 250 million doses annually and will help Latin America prepare for future health emergencies," said Ambroise Fayolle, EIB vice president, quoted in the statement.



The project will improve regional access to vaccines, the resilience of supply chains and preparedness for the emergence of infectious diseases with pandemic potential.

“Through its support for innovation, skills and technology transfer, the EIB contributes to creating a more resilient regional healthcare ecosystem, while also promoting the priorities of the European Union’s Global Gateway strategy,” Fayolle added.

Technical assistance for three candidate vaccines

The operation is supported by the European Commission through the guarantee instrument known as the Human Development Accelerator (HDX) of the European Fund for Sustainable Development Plus (EFSD+).

Under this guarantee, the EIB invests in the health sector through loans to companies, venture debt financing and volume or purchase guarantees. These investments are complemented by new healthcare investments and grants from the Gates Foundation.

This Global Gateway initiative supports investment in healthcare systems, R&D and skills in the health sector, as well as in the manufacture and supply of vaccines, medicines and health technologies in partner countries, the statement continues.

It also announces that, under the HDX guarantee instrument, a 1.5 million euro (US\$1.5 million) grant will be provided as technical assistance for three candidate vaccines against infectious diseases of regional and global importance from VaxThera’s research and development portfolio.

The project, which allows Colombia to establish comprehensive vaccine research and production capacity, will help reduce the country’s dependence on imported vaccines and biological medicines.

In addition, it will contribute to diversifying and strengthening the supply of essential vaccines throughout Latin America and will improve the region’s capacity to respond rapidly to future epidemics and pandemics.

Colombia, regional center for vaccine development and production

The project also alleviates the financing gap in the field of biotechnology innovation, where companies cannot easily access long-term financing due to high initial investment needs, long development timelines and scientific and regulatory risks.

With EIB support, VaxThera will be able to expand its specialized infrastructure, accelerate its research portfolio and mobilize new investments in Colombia’s biotechnology sector.

The operation will also contribute to human capital development, as it will promote the creation of high-value-added jobs in scientific and technical sectors, support the development of local skills and strengthen Colombia’s national biotechnology ecosystem.

By combining production, innovation and technology transfer, the investment strengthens institutional pandemic preparedness capacity and helps Colombia position itself as a regional center for vaccine development and production.

“This investment makes it possible to combine European technology and expertise with Colombian production and research capabilities,” said Jozef Sikela, European Commissioner for International Partnerships, also quoted in the document. “It creates skilled jobs; strengthens R&D, and facilitates more reliable access to essential health products both for Colombia and for Latin America as a whole.”

Fuente: COLOMBIA ONE. Disponible en <https://n9.cl/k7jc2>

Beyond WHO approval, EuBiologics targets global typhoid vaccine market

Sep 27. EuBiologics, the Korean vaccine maker known as the largest supplier of oral cholera vaccines to global health programs for less-developed countries, is lining up its recently approved typhoid conjugate vaccine for international procurement to target an initial UNICEF allocation in the latter half of next year.

EuBiologics' typhoid conjugate vaccine, EuTYPH-C, secured the World Health Organization's prequalification, or PQ in August, becoming the very first vaccine backed by the Research Investment for Global Health Technology Foundation to clear that bar.

"We see the WHO PQ as the first step," Lee

Min-won, executive director of the RIGHT Foundation, said in a joint interview with EuBiologics CEO Baik Yeong-ok at the foundation's office in Seoul on Wednesday.

"(The WHO) PQ gives you the basic qualification to enter public procurement by UNICEF and the like," Lee said.

Before EuTYPH-C, three suppliers from India took up most of the worldwide supply for the WHO PQ-certified typhoid vaccine.

"From the standpoint of international organizations, it is very important to diversify countries and companies and be able to supply reliably with lower-cost products," Lee said, noting that international procurement agencies' funding is shrinking.

Typhoid caused an estimated 6.2 million cases and 72,000 deaths worldwide in 2023, with most of the damage done in South Asia and sub-Saharan Africa, according to the Global Burden of Disease Study. As typhoid conjugate vaccines can be given from 6 months of age and have longer lasting effects than other vaccines, they are regarded as a key countermeasure to the bacterial infection.

EuBiologics' earlier bid for a WHO PQ, which was built on a phase 3 trial in the Philippines, stalled, and the company lacked the money to press on alone. The RIGHT Foundation then picked EuBiologics' project through open competition in 2021 and decided to offer 4 billion won (\$2.95 million) for a phase 3 trial in Kenya and Senegal.

The money came in milestone-based tranches, matched by the company's own 50 percent share. A follow-on 1.78 billion won has, since 2025, financed a study in Senegal evaluating the vaccine's duration of protection.

Although EuBiologics entered a WHO-UNICEF tender late last year expecting approval as soon as mid-2026, it came up empty-handed as the incumbent suppliers from India won the orders.



EuBiologics CEO Baik Yeong-ok (left) and Lee Min-won, executive director of the Research Investment for Global Health Technology Foundation. (RIGHT Foundation)

EuBiologics plans to reopen talks with UNICEF before the year's end as it projects an allocation of 4 million to 5 million doses in the second half of next year, according to Baik.

"No matter how cheaply those in India offer it, we believe we can compete," he said.

A single-dose vial version of EuTYPH-C will ease registration in individual countries outside the UNICEF channel, and Baik pointed out that the company is expected to receive a Korean export license of the single-dose vial version around October with a plan to file for a WHO variation recognition in November.

The EuBiologics CEO likened the addition of EuTYPH-C to the firm's list of WHO PQ-granted vaccines, including its oral cholera vaccine Euvichol, to an old Chinese tale of a parent fretting over two sons, one selling umbrellas, the other straw sandals.

"We were doing only cholera, and now with typhoid as well, we can sell products on rainy days and dry days alike," Baik said.

EuBiologics' meningococcal vaccine co-funded by the RIGHT Foundation and the Gates Foundation is set to finish phase 3 this year, with supply targeted from 2029. The company is also developing a cholera conjugate vaccine it plans to combine with the typhoid shot.

"Once the combination vaccine is out, we will sweep both markets," Baik said.

Set up in 2018 through the partnership between Korea's Ministry of Health and Welfare, the Gates Foundation and Korean life science companies, RIGHT Foundation has committed a cumulative 145.7 billion won to 83 projects with 120 partners from both in and outside of the country.

"Our funding is really small," said Lee, who took the helm of the RIGHT Foundation in March after about three and a half years as the health attache at the Permanent Mission of the Republic of Korea in Geneva.

As the RIGHT Foundation's mostly foreign selection panel now clears more proposals than the budget can cover, it is looking to continue working with the Gates Foundation beyond 2028 when the involved stakeholders are expected to renew their partnership.

"We need to take a further leap," Lee said, calling the prequalification know-how Korean companies are accumulating an asset in itself.

"Our foundation's ultimate goal is achieving global health equity. The main point is to support Korea's health technologies that can make products for helping the public health of low-and middle- income countries".

Fuente: The Korea Herald. Disponible en <https://n9.cl/0wyjm>

La OMS activa su nueva reserva mundial de vacunas frente a mpox

28 sep. El caso recientemente reportado en Ceuta de un menor no acompañado de 13 años que ha dado positivo en mpox ha reavivado cierta inquietud entre parte de la población. El afectado fue inmediatamente puesto bajo supervisión médica y aislamiento, siguiendo los protocolos internacionales de rastreo de contactos y seguimiento. No obstante, no debería extrañarnos si, en los próximos días, se notificara algún caso más dadas las condiciones de hacinamiento e insalubridad que sufre este colectivo desde hace casi dos meses en la ciudad autónoma, y valorando el hecho de que, además, algunas de estas personas podrían proceder de regiones donde esta enfermedad ya es endémica.

Sin embargo, no debemos olvidar que, desde que en 2022 se produjo en Europa un brote de mpox, causado por el virus de la viruela del mono, y se extendió a nivel mundial, esta enfermedad circula en mayor o menor medida por nuestro país, siempre monitoreada por los organismos competentes, entre los que se encuentran, además de los autóctonos, el Centro Europeo para la Prevención y el Control de Enfermedades (ECDC) y la Organización Mundial de la Salud (OMS).

Concretamente, el ECDC mantiene una vigilancia activa sobre los linajes (clado I y clado II) del virus del mpox en Europa, publicando actualizaciones mensuales a través del Sistema de Vigilancia Europeo (EpiPulse).

En su último informe, con datos actualizados a agosto de 2026, se reportan en España 38 casos confirmados del clado I en el último mes (446 en los últimos 12 meses) y un caso del clado II (436 en los últimos 12 meses), tan solo superado por Alemania y Portugal (56 y 39 del clado I, respectivamente).

Así, en los últimos 12 meses, 23 países europeos han notificado 1420 casos del clado I y 19 países notificaron 828 casos del clado II. Por lo tanto, no parece sensato, en principio, crear ningún tipo de alarmismo ante este nuevo caso registrado en Ceuta, pues no es el mpox en nuestro país, ni en el resto del continente, ningún desconocido.

Nueva reserva mundial de vacunas


Con todo, la OMS mantiene su preocupación ante la situación internacional. En su último informe, publicado el pasado 14 de septiembre, evaluó el riesgo general para la salud pública mundial nuevamente como moderado.

La OMS sigue considerando el brote en curso como una emergencia clasificada, con nuevos brotes notificados en múltiples países, más de mil casos confirmados cada mes, y alerta de que en nueve países europeos (Chequia, Francia, Alemania, Irlanda, Italia, Países Bajos, Portugal, Suiza y el Reino Unido) se ha notificado transmisión comunitaria del clado Ib.

Por consiguiente, insta encarecidamente a todos los países y asociados a mantener y sostener la vigilancia y la notificación de los casos, así como las actividades coordinadas de preparación y respuesta en todas las áreas técnicas, de conformidad con las orientaciones de este organismo.

Su director general, el Dr. Tedros Adhanom Ghebreyesus, ya ha declarado que se trata de una emergencia de salud pública de importancia internacional (ESPII) en dos ocasiones, en mayo de 2022 (primera expansión a nivel mundial) y en agosto de 2024, a raíz del importante brote en la República Democrática del Congo que se extendió a otros varios países africanos.

En ese momento, y dada la dificultad de algunos países para acceder a vacunas y atajar la crisis, arrancaba un plan de acción que culminó el pasado 27 de agosto, cuando se puso en marcha por fin



Micrografía electrónica de transmisión del virus Mpox: partículas del virus (doradas y naranjas) encontradas dentro de una célula infectada (púrpura). Crédito: NIAID

una iniciativa mundial de reserva de vacunas contra la mpox, con lo que se crea un mecanismo a largo plazo para que todos los países tengan acceso a estos preparados.

Esta nueva reserva mundial de vacunas, que ya se ha estrenado en Addis Abeba (Etiopía), es un recurso aprobado y financiado por la Junta de la Alianza para las Vacunas (Gavi) y coordinado por el Grupo Internacional de Coordinación del Suministro de Vacunas (GIC). Los asociados del GIC son la Federación Internacional de Sociedades de la Cruz Roja y de la Media Luna Roja (Federación Internacional), Médicos Sin Fronteras (MSF), el Fondo de las Naciones Unidas para la Infancia (UNICEF) y la Organización Mundial de la Salud (OMS).

“El objetivo básico de la iniciativa es aumentar nuestra capacidad de respuesta a las necesidades de los países y lo fundamental es que cualquier país del mundo -no solo los que tienen la capacidad de pagar más- debería poder usar esta herramienta para salvar vidas”, explica la Dra. Sania Nishtar, directora ejecutiva de Gavi. “Tenemos la esperanza de que esta reserva pueda garantizar la seguridad mundial frente a la amenaza de esta enfermedad”.

Fuente: Biotech Magazine and News. Disponible en <https://n9.cl/ph41ch>

New formulation helps RNA vaccines withstand high temperatures

Sep 28. RNA vaccines, which have been proven effective against COVID-19, are now being developed for many other diseases, including cancer. One of the drawbacks to these vaccines is that they require ultracold storage, but researchers from MIT have found a promising way to overcome that limitation.

With help from an AI algorithm, the researchers tweaked the formulation surrounding the lipid nanoparticles that are typically used to deliver mRNA vaccines, making the vaccines more heat-resistant. Using this approach, they formulated vaccines that could remain stable even when stored at room temperature for up to a year, or at nearly 100 degrees Fahrenheit for two months.

When COVID-19 vaccines carried by these particles were administered to mice, they generated just as strong an immune response as an RNA COVID-19 vaccine similar to one developed by Moderna. By using the AI algorithm to predict the optimal formulations for the particles, the researchers were able to cut down the number of experiments they needed to do, which rapidly sped up the development process.

“The real beauty of this algorithm is that we can use it with small data sets,” says Ana Jaklenec, a principal investigator in MIT’s Koch Institute for Integrative Cancer Research. “It’s really hard to run thousands of experiments, so this algorithm allows us to more easily achieve formulations with features that we want — in this case, stability.”

Jaklenec and Robert Langer, the David H. Koch Institute Professor, are the senior authors of the paper, which appears today in *Nature Biotechnology*. Graduate student Jinbi Tian and postdoc Khanh Tran are the lead authors of the paper.

Stable vaccines

RNA is a highly fragile molecule, so researchers stabilize it with lipid nanoparticles (LNPs) that protect the RNA from degradation and help it get into cells. However, these RNA-LNP vaccines still need to

“MIT engineers have found a way to stabilize the lipid nanoparticles used to deliver RNA vaccines, which could allow the vaccines to be more widely distributed.”

be kept cold (-20 to -80 degrees Celsius), which makes it difficult to ship them to regions that don't have cold-storage facilities available.

Making these vaccines more heat-tolerant would not only enable them to be distributed more widely, but could also help researchers develop new vaccines that could be administered through novel methods such as microneedle patches. These patches contain hundreds of vaccine-filled microneedles, which dissolve when the patch is applied to the skin, releasing the vaccine.



To create more stable RNA vaccines, researchers have experimented with adding a variety of excipients — sugars, salts, or polymers — to the LNPs. Jaklenec and Langer recently developed polymer-stabilized LNPs that can withstand higher temperatures, but those LNPs were slightly different from the FDA-approved formulations that were used for the Moderna and Pfizer COVID-19 vaccines.

In their new paper, the researchers wanted to see if they could find a way to make those FDA-approved formulations more stable at high temperatures.

They began by reusing some of the excipients that had worked in their earlier efforts, but they were “really getting stuck,” Jaklenec says. “We were trying to use and screen excipients that we’ve previously used successfully to stabilize LNPs, but it just wasn’t working. It was really frustrating for the team.”

To speed up their progress, the researchers decided to try a machine-learning approach. Working with researchers at MIT’s Computer Science and Artificial Intelligence Lab (CSAIL), they developed an algorithm that can make predictions based on very small datasets.

“We’d used our algorithms for various automated experimental design applications before, but never on a biological problem like vaccine stability,” says Mina Konaković Luković, an assistant professor of electrical engineering and computer science in MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL), who is also an author of the paper. “It was surprising to see how quickly the algorithm converged on a stable formulation — getting there in just a handful of iterations, rather than the exhaustive search that would normally be required.”

The researchers used this algorithm to analyze nearly 50 FDA-approved excipients. For each excipient, the researchers first measured how well it stabilized RNA when incorporated into an LNP. They used these particles to deliver mRNA encoding a protein called firefly luciferase, which produces bioluminescence, into cells. By measuring how much light was emitted by the cells, the researchers could determine how effectively each excipient protected the mRNA.

The researchers chose five of the most promising excipients and used their AI algorithm to predict ratios of those excipients that would best stabilize LNPs similar to those used by Moderna.

Based on those predictions, the researchers tested two formulations at a time in cells, fed those

results back into the algorithm, and generated more predictions. After several rounds, they chose one formulation that appeared promising enough to test in animal studies.

This process took only a few weeks, much less than it would have taken without guidance from the AI algorithm.

“Before we implemented the AI algorithm, we spent several months testing different combinations and also doing the prescreening of all the excipients that we could find, but nothing would get us to 100 percent stability,” Tran says.

Robust immune responses

To test the heat resistance of their new LNP formulation, the researchers used the particles to package Covid-19 mRNA antigens, then dehydrated them using a process called vacuum drying. These particles were then stored at 37 degrees Celsius (98 degrees Fahrenheit) for two months, or at room temperature for one year. Mice that were vaccinated with these particles, even after long-term storage, showed equivalent immune responses to mice that received vaccines carried by LNPs similar to the original Moderna formulation.

The researchers also used their new heat-resistant formulation to create solid microneedle patches that could deliver a SARS-CoV-2 antigen. These patches generated an immune response similar to that produced by the injectable RNA vaccines.

“Our approach broadens the application of not only mRNA vaccines, but also therapeutics or advanced drug-delivery platforms like controlled-release particles or microneedle patches, which requires the formulation to either be in solid state or to be stable at higher temperature,” Tian says.

The researchers also showed that they could use their algorithm to stabilize other LNP formulations, including one similar to those used by Pfizer to deliver its Covid-19 vaccine. This formulation uses the same excipients as the one the MIT team developed for the Moderna LNP, but in a different ratio. For each LNP, once a heat-resistant formulation has been developed, it could be adapted to deliver any type of mRNA payload, the researchers say.

The research was, in part, funded by the Gates Foundation.

Fuente: MIT News. Disponible en <https://n9.cl/bky2wm>

What Dengue Vaccines Can and Cannot Prevent

Sep 29. DENGUE vaccines can reduce illness and hospitalization, but prior infection and viral serotype still shape protection. A narrative review of clinical trials published in *Vaccines* journal, long-term follow-up, and regulatory evidence found that vaccine selection remains closely tied to baseline dengue exposure and local transmission.

The question has growing relevance beyond traditionally endemic regions. The review describes expanding *Aedes* mosquito habitats and reports locally acquired dengue in parts of the United States. For clinicians, travel history remains important, but its absence does not rule out local exposure where transmission occurs.

Why Prior Infection Matters

Four distinct dengue virus serotypes complicate vaccine development. Infection with one serotype provides lasting protection against that serotype but limited protection against the others.

An immune response that does not reliably neutralize a subsequent infection may contribute to antibody-dependent enhancement and more severe disease.

That concern shaped use of CYD-TDV, the first authorized dengue vaccine. Its use was restricted to people with documented previous dengue infection after an increased risk of hospitalization and severe dengue emerged in some recipients who had never been infected. Baseline serostatus is therefore a clinical safety consideration, not simply a predictor of efficacy.

Trial Results Reveal Uneven Protection

In a Phase III trial involving more than 20,000 children and adolescents, two doses of TAK-003 were 73.3% effective against virologically confirmed dengue and 80.2% effective against dengue-related hospitalization during the first year after vaccination. At 4.5 years, the corresponding overall estimates were 61.2% and 84.1%. Protection against some serotypes remains less certain in people without prior dengue infection.

A separate Brazilian Phase III trial found that one dose of Butantan-DV was 79.6% effective against symptomatic dengue over two years. Evidence was drawn mainly from periods when serotypes 1 and 2 circulated. The review also notes serious adverse event reports during its rollout; a causal relationship had not been established, and investigation was ongoing.

Where Dengue Vaccination Fits

The review favors population vaccination where dengue transmission and severe disease burden are sustained. In settings with sporadic transmission, it favors selective assessment based on exposure, previous infection, regulatory indications, and vaccine availability. It concludes that vaccination should accompany mosquito control, case surveillance, clinical preparedness, and continued monitoring of vaccine safety and effectiveness.

Fuente: EUROPEAN MEDICAL JOURNAL. Disponible en

BioPREVAIL and CEPI launch global Biosecurity Innovation Challenge to support 100 Days Mission

Sep 29. The global call invites startups, companies, research groups, laboratories, non-profit organisations and consortia to propose practical biosafety and biosecurity solutions for accelerated vaccine research, development and manufacturing.

- ♦ Selected teams will join a six-month accelerator that combines non-dilutive seed funding, technical mentorship, commercialisation support and access to global health leaders.
- ♦ Applications close Saturday, October 31 at 11:59 p.m. CET. Full details and the application form are available at bioprevail.org/apply.

BioPREVAIL and the Coalition for Epidemic Preparedness Innovations (CEPI) today launched the BioPREVAIL x CEPI Biosecurity Innovation Challenge, a global call for solutions designed to strengthen laboratory biosafety and biosecurity as vaccine research, development and manufacturing accelerate during an epidemic or pandemic response.



The Challenge aims to directly strengthen biosecurity in the setting of rapid response to the emergence of viral pathogens aligned with CEPI's 100 Days Mission, the global goal of making safe, effective and accessible vaccines ready for initial authorisation and manufacturing at scale within 100

days of identifying a new pandemic threat. The Mission has been embraced by leaders of the G7 and G20. The BioPREVAIL x CEPI Biosecurity Innovation Challenge calls on startups and organizations working on the development of vaccines, platform technologies and manufacturing innovations to combat priority pathogens for which no licensed vaccines are currently available.

Three teams will be selected for a six-month accelerator delivered by the Global Health Security Fund through BioPREVAIL, in partnership with CEPI. Each team will be eligible for up to US\$50,000 in non-dilutive seed funding, subject to approval of its project narrative and budget. Teams will retain ownership of their intellectual property. The programme will conclude with an in-person public showcase on the margins of the World Health Assembly in Geneva in May 2027, co-hosted with BioPREVAIL, CEPI, Global Health Security Fund, and Health Innovation Exchange (HIE). Travel and accommodation for participating teams will be provided.

“Speed saves lives, but speed strains the very practices that keep this work secure. We want solutions that hold under that strain, and that still hold once the emergency has passed and everyone’s attention has moved on,” says Dr. Lisa McDonald, President of the Board of Directors, Global Health Security Fund. “That second part is where preparedness usually gets lost.”

The accelerator will pair each team with a lead mentor and provide access to specialists in biocontainment engineering, biosafety, regulatory affairs, fabrication, intellectual property and technology commercialisation. Teams will also take part in the BioPREVAIL Academy, a series of working sessions covering customer discovery, user-centred design, regulatory and intellectual property considerations, fundraising, communications and pitch development.

“Achieving the 100 Days Mission means moving at unprecedented speed without compromising safety or security” said Andrew Hebbeler, Director of Biosecurity, of CEPI. “The BioPREVAIL x CEPI Biosecurity Innovation Challenge will help turn promising ideas into practical safeguards that can be tested and deployed in real-world settings, including where resources and infrastructure are constrained. We are proud to work with BioPREVAIL to advance innovative solutions from around the world that strengthen biosecurity and support the 100 Days Mission.”

Participating teams will receive office hours and milestone reviews, support from a graduate student associate through the Lester Entrepreneurial Scholars Program at The University of Texas at Austin College of Pharmacy, and introductions to potential funders, investors, procurement channels and implementation partners. Each project will also undergo a structured biosecurity review under the commitments of the CEPI-NTI Bio Funders Compact.

The Challenge welcomes technologies, systems innovations, training approaches and empirical studies. Proposed solutions should strengthen biosafety and biosecurity in the context of rapid response to priority pathogens including Chikungunya, Coronaviruses, including COVID-19 and MERS, Filoviruses, Lassa Fever, Mpox, Nipah, Rift Valley Fever, and novel viral threats with epidemic or pandemic potential (also known as “Disease X”). The accelerator welcomes solutions relevant to vaccine research, development or manufacturing. Priority areas include:

- ♦ Analysis without transfer, including approaches that move analysis rather than high-consequence pathogens or sensitive biological material.
- ♦ Chain of custody and tamper evidence for specimens, seed stocks, sequence files and other critical materials across laboratory and transport workflows.
- ♦ Diversion, misuse and insider risk, including detection tools, reporting mechanisms and studies

of the conditions that support early intervention.

- ♦ Rapid confirmation and attribution of unusual or potentially deliberate biological events, including field-ready genomic and laboratory-signature tools.
- ♦ Compliance to action, including systems that convert audit findings into facility improvement plans and monitor progress against standards and training requirements.
- ♦ The digital-biological interface, including safeguards that authenticate biological instructions, gate automated processes and verify the integrity of sequence files and constructs.

Proposals outside these areas may be considered when they meet the Challenge scope. Cross-industry approaches are encouraged, including the adaptation of proven safeguards from aviation, engineering, cybersecurity, fraud detection and other high-reliability fields. Solutions with credible application in low- and middle-income settings will receive consideration.

“The BioPREVAIL x CEPI Biosecurity Innovation Challenge targets vulnerabilities that become even more consequential when vaccine research, development and manufacturing must move at unprecedented speed,” shares McDonald. “We seek practical innovations that can strengthen biosafety and biosecurity under the pressure of CEPI’s 100 Days Mission—including in resource-constrained settings where resilient solutions are needed most.”

Who can apply

Applications are open to startups (especially mid- to later-stage startups) companies, academic and research groups, national and reference laboratories, non-profit organisations and consortia from any country. Applicants do not need to be based in the locations where their solutions would be used, but they must explain how the proposed work applies in those settings.

Eligible proposals must directly strengthen biosecurity in rapid response to especially dangerous pathogens and identify a substantial, achievable advance that can be demonstrated within six months. Shortlisted proposals will undergo biosecurity and dual-use screening. The assessment panel will consider biosecurity impact, applicability under constraint, feasibility, sustainability and value, and the qualifications and availability of the project team. Applicants should consult the published call for the complete eligibility and assessment requirements.

How to apply

The first stage consists of a short online expression of interest and a pitch deck in PDF format. Applicants will be asked to describe the problem, the proposed solution, its current readiness, the milestone to be achieved by month six, how the funding would be used, where the solution can operate, potential users and payers, dual-use or misuse risks, and the support the team would need beyond funding.

Shortlisted teams may be asked for a technical annex, budget, partner letters and materials for formal biosecurity review. Finalists will take part in a live virtual interview before the selection panel.

Applications close on Saturday, October 31 at 11:59 p.m. CET. To review the call and submit an expression of interest, visit bioprevail.org/apply.

Fuente: AZCENTRAL. Disponible en <https://lix.li/XqOA9>

El laboratorio de una crisis global: cómo Bangladés acabó sufriendo el peor brote de sarampión del mundo

30 sep. Bangladés atraviesa desde hace siete meses el peor brote de sarampión registrado actualmente en el mundo, que ha dejado más de 190.000 casos sospechosos, más de 21.500 confirmados y más de 1.100 fallecimientos confirmados y sospechosos, según los últimos datos de las autoridades sanitarias del país. La mayoría de los casos se concentra en niños pequeños, especialmente entre los menores de cinco años. Solo entre el pasado sábado y domingo, la Dirección General de Servicios Sanitarios del país notificó 1.228 nuevos casos sospechosos y nueve muertes de bebés.

El país no es, sin embargo, un caso aislado, sino que el brote se produce en un momento de resurgimiento global del sarampión, una enfermedad altamente contagiosa que en los casos más graves puede provocar la muerte. La Organización Mundial de la Salud (OMS) estima que en 2024, el último año con datos consolidados, se registraron 11 millones de infecciones por sarampión en todo el mundo, casi 800.000 más que antes de la pandemia, y recuerda que esta suele ser una de las primeras enfermedades en reaparecer cuando disminuyen las coberturas vacunales. Ese mismo año, 59 países registraron brotes de la enfermedad, según la OMS. La tendencia ha continuado durante 2026: solo en las Américas se habían notificado más de 51.000 casos confirmados hasta finales de agosto, 4,6 veces más que en el mismo periodo del año anterior. La vacuna contra el sarampión ha evitado cerca de 59 millones de muertes desde 2000, según la OMS.

Los expertos ven en Bangladés la manifestación más extrema de una tormenta perfecta que amenaza a otros países: las brechas de vacunación acumuladas desde la COVID-19 han confluido con otros factores como interrupciones de campañas de inmunización, problemas de suministro, crisis políticas y sistemas sanitarios debilitados. En este país del sur de Asia, el resultado ha sido el brote más mortífero desde 2005.

En las últimas décadas, Bangladés había logrado avances importantes hacia la eliminación del sarampión. “Hasta 2020, la cobertura era cercana al 95%. [El país] se estaba acercando al objetivo de eliminación [de la enfermedad], pero entonces llegó la COVID-19. Hubo una caída drástica de la cobertura del Programa Ampliado de Inmunización, como sucedió en todo el mundo”, explica Rubhana Raqib, científica sénior en el Centro Internacional para la Investigación de Enfermedades Diarreicas (Icddr) especializada en respuestas inmunitarias y enfermedades infecciosas.

Pero a las brechas de inmunización generadas tras la COVID-19, se ha sumado en Bangladés la interrupción del suministro de la vacuna MR contra el sarampión y la rubeola. Aunque hubo algunos episodios puntuales de escasez en 2024, el principal desabastecimiento se produjo en 2025.

A principios del año pasado, el Gobierno interino, surgido tras las protestas estudiantiles de julio de 2024 que precipitaron la caída de la primera ministra Sheikh Hasina, trató de implementar un cambio en el proceso de compra de vacunas. Consistía en abandonar la compra directa vía Unicef y otros organismos para transitar hacia una licitación abierta (open tender), un cambio que terminó generando retrasos y problemas en el suministro. Tras la llegada del nuevo Gobierno después de las elecciones de febrero de 2026, las autoridades cancelaron la implementación de la licitación pública y retornaron al sistema de compra directa.

Esta falta de vacunas contribuyó a que alrededor del 86 % de los niños en Bangladés recibieran en 2025 la segunda dosis de la vacuna contra el sarampión frente al 93 % de 2024, según estimaciones de la OMS y Unicef. Para mantener una inmunidad de grupo suficiente frente a una enfermedad tan contagiosa como el sarampión, la cobertura debe situarse en torno al 95%. En abril de 2025, Unicef advirtió de que unos 400.000 niños no estaban debidamente vacunados contra enfermedades esenciales, entre ellas el sarampión, y otros 70.000 no habían recibido ninguna vacuna, los conocidos como niños cero dosis.

Fuente: EL PAÍS. Disponible en <https://lix.li/Phczw>



VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

EBSCO
Information Services



DOAJ DIRECTORY OF
OPEN ACCESS
JOURNALS



re^{al}alyc.org



HINARI
Research in Health

latindex
Sistema Regional de Información en Línea para
Revistas Científicas de América Latina, el Caribe,
España y Portugal

SeCiMed

Síguenos en redes sociales



@vaccimonitor



@finlayediciones



Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2026/09/23"[Date - Publication] : "2026/09/30"[Date - Publication])) 224 records

[Vaccination gaps and infection risk at dialysis initiation.](#)

Kashiv P, Balwani MR, Tolani P, Pasari A, Saxena K, Kute VB. *World J Nephrol.* 2026 Sep 25;15(3):119445. doi: 10.5527/wjn.119445.PMID: 42626290

[Perfluorooctane sulfonate directly interacts with IRF3 to attenuate antiviral innate immunity.](#)

Liang Q, Li Y, Sun Z, Wang L, Li C, Fang P, Zhang Q, Li J, Sun X, Chen C, Wang C, Guo G, Gao M, Liu S. *Proc Natl Acad Sci U S A.* 2026 Sep 29;123(39):e2536274123. doi: 10.1073/pnas.2536274123. Epub 2026 Sep 21.PMID: 42766748

[Immune boosting to combat Alzheimer's disease: Position statement.](#)

Aaby P, Arnold SE, Benn CS, Ben-Haim S, Bishai W, Dow CT, Faustman D, Gofrit ON, Greenblatt CL, Itzhaki R, Klein B, Lathe R, Netea MG, Sankin A, Scherrer JF, Scholtz-Buchholzer F, Schulz PE, Taquet M, Tariot PN, Weinberg MS; Vaccines for Dementia Study Group. *J Alzheimers Dis.* 2026 Sep 29;13872877261472830. doi: 10.1177/13872877261472830. Online ahead of print.PMID: 42808485

[Measles resurgence in Europe: a public health setback.](#)

De Francesco MA, Quiros-Roldan E. *Expert Rev Anti Infect Ther.* 2026 Sep 28;1-5. doi: 10.1080/14787210.2026.2740115. Online ahead of print.PMID: 42788821

[Antigen prioritization and selection for vaccine design and development: A comprehensive pipeline.](#)

Chelan EM, Pourseif MM, Zarebkohan A, Moghaddam HG, Kiani J, Tohidkia MR, Almasian B, Parhizkar A, Omid Y. *Biotechnol Adv.* 2026 Sep 30;109063. doi: 10.1016/j.biotechadv.2026.109063. Online ahead of print.PMID: 42815812

[Oral vaccine delivery systems: Gastrointestinal barriers, gut microbiota, and emerging engineering strategies.](#)

Wang X, Pan W, Huang J, Zhou Y, Nalinratana N, Rojsitthisak P, Lin Y, Zhao K. *Cell Rep.* 2026 Sep 25;45(10):118038. doi: 10.1016/j.celrep.2026.118038. Online ahead of print.PMID: 42789394

[Rethinking non-human primate models for emerging viral infections after COVID-19.](#)

Kim DY, Hong JJ. *Lab Anim Res.* 2026 Sep 24;42(1):37. doi: 10.1186/s42826-026-00299-1.PMID: 42786507

[Junín virus and Argentine haemorrhagic fever: Virology, pathogenesis, diagnosis, and prevention strategies.](#)

Karanam SK, Uppala PK, Kandra NV, Edhi S. *World J Virol.* 2026 Sep 25;15(3):121066. doi: 10.5501/wjv.121066.PMID: 42780641

[Cytomegalovirus Vaccines in Transplantation: History, Hurdles, and Hope.](#)

Goodwin ML, Limaye AP, Heldman MR. *Transpl Infect Dis.* 2026 Sep 26:e70329. doi: 10.1111/tid.70329. Online ahead of print. PMID: 42800022

[Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality.](#)

Manrai M, Pachisia AV, Jha AA, Shukla R, Hande V, Thareja S. *World J Virol.* 2026 Sep 25;15(3):121081. doi: 10.5501/wjv.121081. PMID: 42781251

[Novel options for the management of *C. difficile*: a look into the future.](#)

Granata G, Petrosillo N, Taglietti F. *Expert Rev Anti Infect Ther.* 2026 Sep 26:1-12. doi: 10.1080/14787210.2026.2739273. Online ahead of print. PMID: 42776479

[mRNA lipid nanoparticle vaccines: current status, challenges and future prospects.](#)

Wu Z, Lou J, Cheng Y, Li M, Wang Z, Liu N, Gao X, Zheng A, Zhang H. *Mol Biomed.* 2026 Sep 28;7(1):186. doi: 10.1186/s43556-026-00600-7. PMID: 42804114

[Redefining leishmaniasis therapy: Innovations in drug discovery and vaccine design.](#)

Pal S, Sharma S, Sharma R. *Microb Pathog.* 2026 Sep 28;221:108845. doi: 10.1016/j.micpath.2026.108845. Online ahead of print. PMID: 42805271

[Exploring the Development of Vaccine Platforms, With a Particular Focus on the COVID-19 Pandemic.](#)

Sällberg M. *Acta Paediatr.* 2026 Sep 24. doi: 10.1111/apa.70762. Online ahead of print. PMID: 42781939

[Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.](#)

Liao W, Shao F, Wang S, Wang Y, Chen X, Zhang Y, Zhang Z, Zai X, Yang Y, Yin Y, Wang Y, Zhang J, Wang J, Xu J. *Signal Transduct Target Ther.* 2026 Sep 23;11(1):404. doi: 10.1038/s41392-026-02787-1. PMID: 42778529

[Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.](#)

Gupta MK, Vadde R, Nagaraju GP. *MedComm (2020).* 2026 Sep 25;7(10):e71009. doi: 10.1002/mco2.71009. eCollection 2026 Oct. PMID: 42798783

[Design of Epitope-Focused Vaccines via Epitope Cleavage.](#)

Pham DM, Costello RM, Bruun TUJ, Kim PS. *ACS Cent Sci.* 2026 Jul 17;12(9):1348-1359. doi: 10.1021/acscentsci.6c00476. eCollection 2026 Sep 23. PMID: 42799170

[Functionalized albumin-based dual-delivery system potentiates chemoimmunotherapy via differential targeting.](#)

Wang Y, Feng J, Xiong K, Li X, Qin K, Xue Y, Gong T. *J Mater Chem B.* 2026 Sep 24. doi: 10.1039/d6tb01373b. Online ahead of print. PMID: 42785352

[Carbohydrate functionalization modulates the mucosal transport and immunological activity of chitosan nanoparticles.](#)

Colaço M, Panão-Costa J, Del Favero E, Ricci C, Patterlini V, Climani G, Ferraboschi I, Sissa C, Lebre F, Alfaro-Moreno E, Sonvico F, Borges O. *Int J Biol Macromol*. 2026 Sep 26;383(Pt 1):154646. doi: 10.1016/j.ijbiomac.2026.154646. Online ahead of print. PMID: 42790565

[Mutations that positively affect *Bandavirus* glycoprotein function in VSV-vectored vaccines.](#)

Petch RJ, Hicks P, Westover JB, Gowen BB, Bates P. *J Virol*. 2026 Sep 24:e0131126. doi: 10.1128/jvi.01311-26. Online ahead of print. PMID: 42782148

[Rationale for a live-attenuated vaccine for cryptosporidiosis.](#)

White AC Jr, Dann SM, Castellanos-Gonzalez A. *J Infect Dis*. 2026 Sep 23:jiag471. doi: 10.1093/infdis/jiag471. Online ahead of print. PMID: 42775396

[Messenger RNA \(mRNA\) Therapeutics: Advances, Challenges, and Future Perspectives in Modern Medicine.](#)

Sharma U, Pandey V, Gupta H, Soni S, Rathee S, Patil UK. *Curr Pharm Des*. 2026 Sep 25. doi: 10.2174/0113816128453800260831114811. Online ahead of print. PMID: 42786888

[Vaccination coverage among migrant and refugee populations in Uganda: A narrative review of challenges and recommendations.](#)

Nakachwa SM, Okorobe PM, Onama J. *Glob Public Health*. 2026 Dec 31;21(1):2735676. doi: 10.1080/17441692.2026.2735676. Epub 2026 Sep 23. PMID: 42776600

[A recombinant pseudorabies virus co-expressing G2b and G2c S1 broadens neutralizing antibody responses against PEDV variants and enhances pre-existing vaccine-induced antibody responses.](#)

Pan Q, Yan F, Liu S, Wang X, Zhu B, Ye J, Cao S, Zhang A, Si Y. *Int J Biol Macromol*. 2026 Sep 30:154682. doi: 10.1016/j.ijbiomac.2026.154682. Online ahead of print. PMID: 42815667

[Engineered exosomes for oral administration: breaking gastrointestinal barriers for disease therapy.](#)

Ma Y, An T, Wu P, Li D, Wang R, Song H, Liu Q, He N. *J Drug Target*. 2026 Sep 29:1-16. doi: 10.1080/1061186X.2026.2733612. Online ahead of print. PMID: 42741975

[Discovery and characterization of a pigment produced by *Streptococcus pyogenes*.](#)

Pathak S, DeVinney T, Gogos A, Woods RA, Anderson CM, Chang JC, Federle MJ. *mBio*. 2026 Sep 23:e0134826. doi: 10.1128/mbio.01348-26. Online ahead of print. PMID: 42775910

[Measles-Related Macular Necrotizing Retinitis in an Unvaccinated Adult: A Case Report.](#)

Bolletta E, Bruno R, Trinco A, Zoboli G, De Simone L, Gozzi F, Gentile P, Adani C, Invernizzi A, Cimino L. *Ocul Immunol Inflamm*. 2026 Sep 23:1-5. doi: 10.1080/09273948.2026.2735408. Online ahead of print. PMID: 42779127

[Serotype-specific Immunity and Association With Pneumococcal Carriage Following 3+1, 3+0, and 2+1 Schedules of 10-valent Pneumococcal Conjugate Vaccine.](#)

Ong DS, Toh ZQ, Temple B, Nguyen CD, Phan TV, Dai VTT, Balloch A, Higgins RA, Ortika BD, Beissbarth J, Bright K, Vientrung K, Spry L, Nation ML, Hong NVP, Toan NT, Hoan PT, Cheung YB, Smith-Vaughan H, Satzke C, Huu TN, Mulholland K, Licciardi PV. *J Infect Dis.* 2026 Sep 23;234(3):e702-e713. doi: 10.1093/infdis/jiag157. PMID: 41818666

[Detection and genomic characterization of an emerging bovine coronavirus in Southwest China.](#)

Ren Y, Banma W, Su Y, Ye X, Tang C, Chen X, Yue H. *Vet J.* 2026 Sep 23;320:106893. doi: 10.1016/j.tvjl.2026.106893. Online ahead of print. PMID: 42772549

[Cell-Mediated Immunity of mRNA-1283 **Vaccine** Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies.](#)

Frey AW, Budigi Y, Girard B, Santos G, Harmon C, Hasan MM, McGrath S, Paila YD, Carfi A, Edwards D, Wahid R, Das R, Chalkias S. *J Infect Dis.* 2026 Sep 23;234(3):e522-e530. doi: 10.1093/infdis/jiag248. PMID: 42240400

[CAR-based therapies in systemic autoimmunity: from deep immune depletion toward durable immune reset.](#)

Zhang H, Wu B, Wan H, Wu K, Si T, Zhou Z, Peng Z. *Int Immunopharmacol.* 2026 Sep 23;189:117461. doi: 10.1016/j.intimp.2026.117461. Online ahead of print. PMID: 42784892

[Influenza **vaccine** effectiveness against influenza-related medical visits, hospitalization and death among adults aged 65 years and older in Taiwan: interim 2024-2025 season result using standard-dose inactivated influenza **vaccine**.](#)

Tsou TP, Huang YT, Lin CY, Chu PW, Huang YT. *Vaccine.* 2026 Sep 29;93:129165. doi: 10.1016/j.vaccine.2026.129165. Online ahead of print. PMID: 42810173

[Effect of Temporary Methotrexate Discontinuation on **Vaccine** Immunogenicity and Disease Flare in Rheumatoid Arthritis: A Systematic Review.](#)

Tahir A, Iftikhar A, Kumar K, Nawaz Y, Fatima P, Saeed M, Sarwar SS, Khalid F, Javaid A, Akhtar B, Zafar B, Ahmad A, Siddiqui E, Khan MS, Khan MM. *Ann Pharmacother.* 2026 Sep 30;10600280261489586. doi: 10.1177/10600280261489586. Online ahead of print. PMID: 42813242

[Targeting a site of vulnerability on circumsporozoite protein inhibits *Plasmodium vivax* malaria infection.](#)

Visweswaran GRR, Mahdavi P, Vijayan K, Ntumngia FB, Staker BL, Barnes SJ, Subramani PA, Raappana A, Dambrauskas N, Glennon EKK, Kolli SK, Ogbondah MM, Watson A, Camargo N, Sankaran B, Thawornpan P, Jenwithisuk R, Myler PJ, Kappe SHI, Roobsoong W, Chootong P, Sattabongkot J, Kaushansky A, Vigdorovich V, Adams JH, Sather DN. *Immunity.* 2026 Sep 24:S1074-7613(26)00376-6. doi: 10.1016/j.immuni.2026.09.001. Online ahead of print. PMID: 42785294

[Computational identification of conserved B- and T-cell epitopes for multi-epitope peptide **vaccine** design against bovine leukemia virus.](#)

Sevinc Temizkan S, Kökkaya S, Temizkan MC. *Virus Genes.* 2026 Sep 30. doi: 10.1007/s11262-026-02279-y. Online ahead of print. PMID: 42814220

[Exploiting Tumor Cell Invasiveness to Construct an Isolated Niche for Postoperative Immunotherapy.](#)

Cheng Y, Pang B, Wu Q, Yang C, Tang R. *Adv Mater.* 2026 Sep 24:e75102. doi: 10.1002/adma.75102. Online ahead of print. PMID: 42782194

[Radiotherapy-induced PD-L1 conversion in esophageal squamous cell carcinoma: From multidimensional mechanisms to clinical rescue strategies.](#)

Ding Y, Jing W, Zhu H. *Biochim Biophys Acta Rev Cancer.* 2026 Sep 23;1881(6):189703. doi: 10.1016/j.bbcan.2026.189703. Online ahead of print. PMID: 42778075

[Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy.](#)

Peng Q, Wong YC, Cheng WY, He Y, Xie C, Shi Y, Wang T, Du Y, Yang X, Wang Z, Wang H, Lu H, Chen Z, Jin X; ICVAX Phase I clinical trial study team. *J Infect Dis.* 2026 Sep 23;234(3):361-372. doi: 10.1093/infdis/jiag320. PMID: 42446368

[A flagellin-S100A9 fusion vaccine breaks immune tolerance and suppresses experimental lung metastasis in mice.](#)

Zeng Z, Qiu S, Zhuo K, Li X, Huang S, Wang L, Zou P, Wei X, Duan H, Cao Y, Zhong M. *Pharmacol Res.* 2026 Sep 29;233:109656. doi: 10.1016/j.phrs.2026.109656. Online ahead of print. PMID: 42810628

[Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review.](#)

Aminu K, Amzat J, Nwebo RA, Nnannah PC, Ezeagu CN, Edukugho AA, Omobowale O, Shehu A, Jayasinghe YA, Amzat G, Kanmodi KK. *Health Sci Rep.* 2026 Sep 25;9(10):e73254. doi: 10.1002/hsr2.73254. eCollection 2026 Oct. PMID: 42799168

[Parental awareness, knowledge, and hesitancy toward HPV vaccination for adolescents: A cross-sectional study.](#)

Güven D, Köle MT, Örün E, Çaylan N, Küçük E, Kandemir I, Öztürk S, Kondolot M. *Arch Argent Pediatr.* 2026 Sep 30;124(5):e202611021. doi: 10.5546/aap.2026-11021.eng. Epub 2026 Jun 18. PMID: 42301822

[Seroprevalence and associated factors of foot-and-mouth disease virus antibodies in cattle in Africa and Asia: A systematic review and meta-analysis.](#)

Li LM, Zhao FF, Han L, Xu XY, Zhao HN, Guo YL, Gao MC. *Vet J.* 2026 Sep 25;320:106897. doi: 10.1016/j.tvjl.2026.106897. Online ahead of print. PMID: 42790689

[Influenza vaccine effectiveness against influenza A-associated hospitalization and severe in-hospital outcomes among adults in the United States, 2024-2025.](#)

Lewis NM, Cleary S, Harker EJ, Safdar B, Ginde AA, Peltan ID, Gaglani M, Columbus C, Martin ET, Lauring AS, Steingrub JS, Hager DN, Mohamed A, Johnson NJ, Khan A, Duggal A, Wilson JG, Qadir N, Busse LW, Kwon JH, Exline MC, Vaughn IA, Mosier JM, Harris ES, Zhu Y, Grijalva CG, Halasa NB, Chappell J, Surie D,

Dawood FS, Ellington S, Self WH; Investigating Viruses in the Acutely Ill (IVY) Network. Clin Infect Dis. 2026 Sep 26;ciag540. doi: 10.1093/cid/ciag540. Online ahead of print. PMID: 42790883

[Systemic Inflammation and the Persistence of **Vaccine**-Induced Hepatitis B Immunity in Healthcare Workers.](#)

Çoruh Akyol B, Dağışan T, Çankaya S, Enginyurt Ö. Med Sci Monit. 2026 Sep 28;32:e955023. doi: 10.12659/MSM.955023. PMID: 42802526

[Bridging the translational gap: an operational classification and quantitative framework for accelerating enteric **vaccine** research using animal models.](#)

Koley H, Mukherjee A, Mukhopadhyay AK, Das S, Howlader DR. Vaccine. 2026 Oct 24;92:129167. doi: 10.1016/j.vaccine.2026.129167. Epub 2026 Sep 23. PMID: 42784864

[Measles Whole Genome Sequencing by an Illumina Tiled Amplification Method.](#)

Zubach 5th, Ashfaq S, Van Driel S, Kaplen B, Peters G, Laminman 5th, Go A, Bonner C, Graham M, Hiebert J. J Virol Methods. 2026 Sep 29;115477. doi: 10.1016/j.jviromet.2026.115477. Online ahead of print. PMID: 42810550

[Re-emergence of *Brucella* species: epidemiology and pathogenesis.](#)

Tamanna S, Kim D-M, Lee B, Kim C-M, Lee Y-M. Clin Microbiol Rev. 2026 Sep 30:e0013926. doi: 10.1128/cmr.00139-26. Online ahead of print. PMID: 42813793

[The importance of reporting notifiable infectious diseases - the Swiss reporting system.](#)

Raess M, Celant A, Mäusezahl M. Swiss Med Wkly. 2026 Sep 25;156:5508. doi: 10.57187/5508. PMID: 42801454

[Sleep deprivation as a multi-system physiological stressor: A review of shared mechanisms and clinical implications.](#)

Ghanem FK, Attarian H, Kabrita CS. Sleep Med. 2026 Sep 23;148:109284. doi: 10.1016/j.sleep.2026.109284. Online ahead of print. PMID: 42785218

[Pathological, microbiological and immunological performance of three tuberculosis **vaccine** candidates in goats.](#)

Fernández-Veiga L, Elguezabal N, Fuertes M, Geijo MV, Molina E, Mugica-Unamuno M, Ramos A, Espada Y, Melgarejo C, Vidal E, Pérez de Val B, Juste RA, Garrido JM, Sevilla IA. Vaccine. 2026 Sep 26;93:129196. doi: 10.1016/j.vaccine.2026.129196. Online ahead of print. PMID: 42800088

[Herpes Zoster Vaccination as Cardiovascular Prevention in Adults with Heart Disease.](#)

Facila Rubio L, Pallarés-Carratalá V, Cordero A, Pérez Silvestre J, Bonanad Lozano C. Cardiovasc Drugs Ther. 2026 Sep 28. doi: 10.1007/s10557-026-07966-4. Online ahead of print. PMID: 42803885

[Burden of herpes zoster and recombinant zoster **vaccine** willingness in systemic lupus erythematosus: A single-center cohort study.](#)

Fujisawa Y, Watanabe R, Ishihara R, Fujita Y, Katsushima M, Fukumoto K, Yamada S, Hashimoto M. *Lupus*. 2026 Sep 28;9612033261493819. doi: 10.1177/09612033261493819. Online ahead of print. PMID: 42803531

[Serious cardiac events in the COVID-19 era in the paediatric population: what did we learn?](#)

Safi D, Toutounji K, Arabi M. *Cardiol Young*. 2026 Sep 24;1-17. doi: 10.1017/S1047951126123956. Online ahead of print. PMID: 42779283

[COVID-19 **vaccine**-associated autoimmune thyroid eye disease: Graves' orbitopathy.](#)

Murugan AK, Afnan R, Alzahrani AS. *Endocrine*. 2026 Sep 28;91(1):320. doi: 10.1007/s12020-026-04795-1. PMID: 42804126

[An intranasal bivalent **vaccine** induces antigen-specific humoral and Th1/Th17 cellular immunity and protects young and aged mice against MRSA and *Pseudomonas aeruginosa* skin and soft tissue infections.](#)

Maiti S, Lu T, Dietz ZK, Whittier SK, Picking WD, Picking WL. *Infect Immun*. 2026 Sep 24:e0035526. doi: 10.1128/iai.00355-26. Online ahead of print. PMID: 42782163

[Multicomponent vaccination against seasonal influenza and COVID-19: a strategy to address the continued global burden of disease in adults.](#)

Schaffner W, Gravenstein S, Kissler S, Cornely OA, Mehta D, Cenoz MG, Vivic N, Rudin D. *Vaccine*. 2026 Sep 25;93:129082. doi: 10.1016/j.vaccine.2026.129082. Online ahead of print. PMID: 42790130

[Infectious triggers in IgA vasculitis in children: current evidence, causal attribution and immunopathogenic mechanisms.](#)

Filippatos F, Venieri D, Tsigkrou E, Karava V, Miliaraki M, Kakleas K. *Rheumatol Int*. 2026 Sep 26;46(10):267. doi: 10.1007/s00296-026-06295-x. PMID: 42799772

[Real-world safety data of human papillomavirus vaccines after marketing in Shandong, China, August 2017-October 2025.](#)

Xie M, Li H, Qiu X, Kang X, Wei J, Liu S, Tao Z, Zhang Y. *Hum Vaccin Immunother*. 2026 Dec;22(1):2731696. doi: 10.1080/21645515.2026.2731696. Epub 2026 Sep 25. PMID: 42788243

[Evaluation of the immunogenicity of hepatitis B vaccination in hematopoietic stem cell transplant recipients vaccinated with a hexavalent **vaccine** compared with patients vaccinated with a combined hepatitis A and B **vaccine**.](#)

Montes Camiño LM, Aldea M, Martínez C, García-Basteiro AL, Mena G. *Vaccine*. 2026 Sep 27;93:129183. doi: 10.1016/j.vaccine.2026.129183. Online ahead of print. PMID: 42801864

[Malaria vaccines are here-can surveillance keep pace?](#)

Nema S, Bharti PK, Mohammed A, Malhotra P. *Trans R Soc Trop Med Hyg*. 2026 Sep 30:trag118. doi: 10.1093/trstmh/trag118. Online ahead of print. PMID: 42813265

[Empowering cancer therapy: the promise of natural adjuvants.](#)

De T, Bibi R, Sarkar K. Mol Biol Rep. 2026 Sep 27;53(1):1627. doi: 10.1007/s11033-026-12800-z. PMID: 42801348

[Brief report: Effectiveness and safety of recombinant zoster **vaccine** in inflammatory bowel disease patients aged 18 years and older: A matched cohort and self-controlled case series study.](#)

Humayun M, Sy LS, Rayens E, Qian L, Wu J, Ackerson BK, Luo Y, Cheng Y, Patel AR, Solano Z, Amundsen B, De Jesus J, Ku JH, Chmielewski-Yee E, Oraichi D, Seifert H, Yun H, Tseng HF. Hum Vaccin Immunother. 2026 Dec;22(1):2730840. doi: 10.1080/21645515.2026.2730840. Epub 2026 Sep 28. PMID: 42804491

[Functional O-specific polysaccharide-specific antibody responses in young children following Shigella infection in Bangladesh.](#)

Bernshtein B, Zhiteneva JA, Janardhanan J, Wagh C, Kelly M, Verma S, Faherty CS, Nikolov A, Jung W, Basher SR, Amin MA, Mahamud S, Rajib NH, Chowdhury F, Khan AI, Charles RC, Xu P, Kováč P, Chakraborty S, Kaminski RW, Alter G, Bhuiyan TR, Qadri F, Ryan ET. Cell Rep Med. 2026 Sep 24:103076. doi: 10.1016/j.xcrm.2026.103076. Online ahead of print. PMID: 42785303

[Aboriginal and Torres Strait Islander adolescent and parent perspectives on human papillomavirus vaccination through the School Immunisation Program in Queensland, Australia: a qualitative study.](#)

Butler TL, Anderson K, Morseu-Diop A, Brotherton JML, Cunningham J, Jaure A, Garvey G, AhWing E, Clements V, Egert S, Lomas F, Ross C, Whop LJ. Vaccine. 2026 Sep 28;93:129170. doi: 10.1016/j.vaccine.2026.129170. Online ahead of print. PMID: 42805053

[Sociodemographic and Lifestyle Factors Associated With COVID-19 **Vaccine** Uptake in a Mixed Urban-Rural Population in Eastern Poland.](#)

Karczmarz S, Rabin KH, Oberska J, Kuś A, Silczuk A, Owoc J, Łoś M. Med Sci Monit. 2026 Sep 23;32:e951865. doi: 10.12659/MSM.951865. PMID: 42776929

[Trimethyl chitosan-hyaluronic acid nanoparticle-loaded hydrogel potentiates dendritic cell-based immunotherapy against breast cancer.](#)

Eteghadi A, Taghipour N, Hosseinzadeh S, Hashemi SM, Ghasemi FS, Soleimani M. Biochem Biophys Res Commun. 2026 Sep 24;838:154605. doi: 10.1016/j.bbrc.2026.154605. Online ahead of print. PMID: 42805013

[Coverage and appropriateness of influenza vaccination in adults \$\geq 60\$ y: Provider contribution and adherence to Italian national recommendations.](#)

Amicizia D, Grammatico F, Massaro E, Schenone I, Marchini F, Astengo M, Fiorano A, Orsi A, Icardi G, Ansaldi F; ESDA Network. Hum Vaccin Immunother. 2026 Dec;22(1):2736958. doi: 10.1080/21645515.2026.2736958. Epub 2026 Sep 25. PMID: 42788870

[Supply, demand and use of economic evidence in **vaccine** policymaking in Africa: A scoping review.](#)

Mazuba E, Kazibwe J, Chirwa J, Banda A, Kaonga O, Chitah B, Orangi S, Barasa E, Masiye F. PLOS Glob Public Health. 2026 Sep 24;6(9):e0007080. doi: 10.1371/journal.pgph.0007080. eCollection 2026. PMID: 42784554

[Projected effects of removing school-entry vaccination requirements on measles transmission in Florida.](#)

Oveson A, Gumel AB. *Proc Natl Acad Sci U S A*. 2026 Oct 6;123(40):e2610455123. doi: 10.1073/pnas.2610455123. Epub 2026 Sep 28. PMID: 42804627

[COVID-19 vaccination during pregnancy or lactation and infant growth and health care utilization.](#)

Kharbanda EO, Cao J, Vazquez-Benitez G, Ehresmann K, Seburg EM, DeSilva MB, Daida YG, Vesco KK, Sidebottom A, Effros R, Lipkind HS, Palmsten K. *Acad Pediatr*. 2026 Sep 28:103477. doi: 10.1016/j.acap.2026.103477. Online ahead of print. PMID: 42805288

[Noninvasive Transdermal **Vaccine** Platform Using Deep Eutectic Solvents for Cancer Immunotherapy.](#)

Fujita N, Toyofuku K, Wakabayashi R, Kawaguchi Y, Kamiya N, Goto M. *ACS Appl Bio Mater*. 2026 Sep 29. doi: 10.1021/acsabm.6c00559. Online ahead of print. PMID: 42809809

[Mechanistic Digital Model for Real-Time Monitoring and Optimization of Adenovirus Production.](#)

Xu X, Rüdiger D, Shin J, Chahal S, Kamen A. *Biotechnol Bioeng*. 2026 Sep 30. doi: 10.1002/bit.70395. Online ahead of print. PMID: 42813361

[Computational Design of a Trivalent Multi-Epitope mRNA **Vaccine** Candidate Against Western, Eastern, and Venezuelan Equine Encephalitis Viruses.](#)

Qin R, Luo Y, Zhou Z, Xu Y, Wu X, Hou Y, Chen J, Zhu F, Pan P. *Pharm Res*. 2026 Sep 24. doi: 10.1007/s11095-026-04192-3. Online ahead of print. PMID: 42786366

[Nationwide Multicenter Laboratory-Based Analysis of Varicella-Zoster Virus IgG and IgM Seropositivity in Korea, 2014-2024.](#)

Bang HI, Lee A, Lee J, Yu S, Choi HW, Yoo SJ, Kim YR, Kim JH, Kim HS. *Ann Lab Med*. 2026 Sep 23. doi: 10.3343/alm.2026.0003. Online ahead of print. PMID: 42772846

[High-content image-based screening reveals vaccinia virus membrane proteins as potential regulators of LC3 lipidation.](#)

Krause M, Yakimovich A, Vágó N, Drexler I, Mercer J. *Microbiol Spectr*. 2026 Sep 23:e0122126. doi: 10.1128/spectrum.01221-26. Online ahead of print. PMID: 42773059

[\[Intervention strategies to improve adult vaccination coverage: a review and future directions\].](#)

Li L, He JY, Zhang S, Peng HX, Yu WZ, Zhang ZN, Song YF, Cao L, Ye JK, Yin ZD. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2026 Sep 23;60:1-7. doi: 10.3760/cma.j.cn112150-20260128-00084. Online ahead of print. PMID: 42773991

[Evaluation of surveillance performance and determinants for priority **vaccine**-preventable diseases in Niger State, Nigeria: A CDC 2001 Guideline-based multilevel analysis.](#)

Awoyale OD, Jimoh A, Dede A, Rauf RI, Mustafa A, Sowade TA, Gimba PB, Ibrahim I, Akpen CN, Eugene EC, Erekosima GF, Okekeigwe C, Tarfa MJ, Isiaka SD, Okagbue H, Atobatele S, Sampson S. *PLOS Glob*

Public Health. 2026 Sep 23;6(9):e0005928. doi: 10.1371/journal.pgph.0005928. eCollection 2026.PMID: 42776953

[Engineering a Non-Aphid-Transmissible Mild Mutant of Zucchini Yellow Mosaic Virus for Cross Protection.](#)

Xu X, Zhang Y, Wang J, Fan C, Ren Q, Bai Y, Geng C, Zhang H, Tian Y, Luan Y, Li X. *Phytopathology*. 2026 Sep 26. doi: 10.1094/PHTO-05-26-0175-R. Online ahead of print.PMID: 42799996

[Reviewing RVUs: Relevant Billing Codes for Infectious Diseases Clinicians.](#)

Li CN, Cast J, Patel S, Heald-Sargent T, Murtagh K, Jhaveri R. *J Pediatric Infect Dis Soc*. 2026 Sep 25;piag105. doi: 10.1093/jpids/piag105. Online ahead of print.PMID: 42788890

[Immunological evaluation of Brucella antigens formulated with two agonists of toll-like receptor 4 and 3 against brucellosis in BALB/c mice.](#)

Sadeghi Z, Fasihi-Ramandi M, Bouzari S. *Microb Pathog*. 2026 Sep 23;221:108846. doi: 10.1016/j.micpath.2026.108846. Online ahead of print.PMID: 42772472

[From laboratory to field: Progress and prospects of the phased conditional approach in two decades of sterile insect technique research against Aedes aegypti in Indonesia.](#)

Ernawan B, Sasmita HI, Guswenrivo I, Kesuma AP, Kartika T, Mujiyanto M, Widawati M, Suryaningtyas NH, Nurjanah S, Nirwan M, Ramadhani T, Wahono T, Isnani T, Putra RE, Ahmad I. *Acta Trop*. 2026 Sep 25;283:108346. doi: 10.1016/j.actatropica.2026.108346. Online ahead of print.PMID: 42790571

[Proteome-wide characterization of Plasmodium vivax antigens using a high-density peptide array.](#)

Asawa R, Hazzard B, Ko K, Tebben K, Tan J, Cantaert T, Berry A, Tolia N, Popovici J, Serre D. *PLoS Pathog*. 2026 Sep 28;22(9):e1014621. doi: 10.1371/journal.ppat.1014621. Online ahead of print.PMID: 42804534

[Backward bifurcations in discrete-time epidemic models with vaccination.](#)

Ackleh AS, Jahangir J, Veprauskas A. *Bull Math Biol*. 2026 Sep 23;88(10):183. doi: 10.1007/s11538-026-01752-x.PMID: 42776322

[Differing influenza vaccine uptake and recommendation behavior among healthcare workers in primary health centers, secondary and tertiary hospitals, and schools in a metropolis of southern China.](#)

Lin D, Zhang X, Hu J, Li X, Yao L, Lu J, Wang Z, Chen Y, Lu Y. *Expert Rev Vaccines*. 2026 Dec;25(1):2736329. doi: 10.1080/14760584.2026.2736329. Epub 2026 Sep 23.PMID: 42775460

[Lectins as Adjuvants and Vaccine Delivery Systems: A Mini-Review.](#)

de Sousa GF, Goncalves CN, de Oliveira Della Senta D, da Silva Pinto L. *Recent Adv Drug Deliv Formul*. 2026 Sep 24. doi: 10.2174/0126673878465675260827101211. Online ahead of print.PMID: 42786865

[Cationic surfactant-dependent enhancement of antigen-specific cellular immunity by a biodegradable nanoparticle vaccine.](#)

Huete-Carrasco J, Aboagye J, Neple D, McClean S, Courant T, Lavelle EC. *Vaccine*. 2026 Sep 27;93:129195. doi: 10.1016/j.vaccine.2026.129195. Online ahead of print.PMID: 42801865

[Low birthweight and prematurity, but not malaria chemoprevention, are associated with reduced pneumococcal **vaccine** immunogenicity in Ugandan infants.](#)

Musinguzi K, Sbarra AN, Bach F, Nankya F, Achom KB, Mwubaha C, Nayebare P, Nansubuga E, Kakuru A, Kizza J, Maato Z, Arinaitwe E, Press KD, Bagaya BS, Tukwasibwe S, Ssewanyana I, Nankabirwa JI, Kanya MR, Dorsey G, Takahashi S, Jagannathan P. *J Infect Dis.* 2026 Sep 28;jiag488. doi: 10.1093/infdis/jiag488. Online ahead of print. PMID: 42803282

[NaCl-Based In Situ Tumor **Vaccine** via Amplification of Ablation-Induced Adaptive Immunity for Enhanced Microwave-Metalloimmunotherapy.](#)

Chen Z, Jiang J, Fan F, Chen S, Zhang D, Dou J, Liang P, Meng X, Yu J. *Adv Healthc Mater.* 2026 Sep 29:e71784. doi: 10.1002/adhm.71784. Online ahead of print. PMID: 42811381

[The commercialization of "unvaccinated" blood: A cross-sectional analysis of organizations marketing services based on donor COVID-19 vaccination status.](#)

Jacobs JW, Booth GS, Raza S. *Transfusion.* 2026 Sep 25. doi: 10.1111/trf.70414. Online ahead of print. PMID: 42788479

[Assessing dengue knowledge, attitudes and preventive practices in France and Italy: A cross-sectional study using participatory surveillance cohorts.](#)

Calmon L, De Gaetano A, Mazzoli M, Gozzi N, Debin M, Turbelin C, Marmorat R, Perra N, Barrat A, Colizza V, Paolotti D. *PLOS Glob Public Health.* 2026 Sep 23;6(9):e0007162. doi: 10.1371/journal.pgph.0007162. eCollection 2026. PMID: 42776964

[Linear DNA expression cassette encapsulated in lipid nanoparticles confers complete protection against influenza A virus in mice.](#)

Lai DC, Nguyen TN, Trinh GP, Vu HLX. *mSphere.* 2026 Sep 29;11(9):e0013526. doi: 10.1128/msphere.00135-26. Epub 2026 Sep 4. PMID: 42695687

[Availability and accessibility of SARS-CoV-2 vaccines among rural populations in sub-Saharan Africa: a systematic review and meta-analysis protocol.](#)

Nyangi E, Bukagu Y, Paul M, Massawe N, Mkumbwa R, Mwasanga E, Ruwaichi T, Mawi N, Abihudi S, Luoga P. *BMJ Open.* 2026 Sep 24;16(9):e119874. doi: 10.1136/bmjopen-2026-119874. PMID: 42785944

[Distinct mechanisms of neutralization by antibodies targeting a conserved pneumovirus F epitope.](#)

Ols S, Arcoverde Cerveira R, Borst AJ, Bermúdez-Méndez E, Gegenfurtner F, Eray E, Weidle C, Miranda MC, Peng Z, Carr KD, Skotheim R, Kochmann J, Brunette N, Lenart K, Hanke L, Karlsson Hedestam GB, Perez L, Antanasijevic A, King NP, Loré K. *bioRxiv [Preprint].* 2026 Sep 24:2026.09.21.749132. doi: 10.64898/2026.09.21.749132. PMID: 42818254

[Comparative evaluation of three protein nanoscaffolds for IHN V G ectodomain display in rainbow trout \(*Oncorhynchus mykiss*\).](#)

Chen L, Liu M, Zhang Z, Lu Y, Zhao Z, Zhu B. Fish Shellfish Immunol. 2026 Sep 24;179:111731. doi: 10.1016/j.fsi.2026.111731. Online ahead of print. PMID: 42785398

[Indirect Effect of Pneumococcal Conjugate Vaccines on Pneumococcal Colonization: Persistence and Dynamics of Vaccine Serotypes in Sicily \(Italy\) 11 Years Postintroduction, 2009-2020.](#)

Tramuto F, Randazzo G, Santino A, Sferlazza G, Previti A, Graziano G, Costantino C, Mazzucco W, Amodio E, Vitale F, Maida CM. J Infect Dis. 2026 Sep 23;234(3):e690-e701. doi: 10.1093/infdis/jiag150. PMID: 41791422

[The truncated major pilin subunit SBP2' contributes to Streptococcus suis meningitis by interacting with host plasminogen.](#)

Guo G, Li P, Zhou Y, Li Q, Yu Y, An J, Zhang W. Appl Environ Microbiol. 2026 Sep 23;92(9):e0126726. doi: 10.1128/aem.01267-26. Epub 2026 Aug 10. PMID: 42573261

[A quantitative analysis of barriers to college students' seasonal vaccination intentions and behaviors.](#)

Clemens KS, Matkovic J. J Am Coll Health. 2026 Sep 25:1-11. doi: 10.1080/07448481.2026.2731254. Online ahead of print. PMID: 42791254

[Healthy Trust and Pandemic Readiness in the Context of Messenger RNA Vaccines: Protocol for a Sequential Deliberative Dialogue Study.](#)

Plamondon K, Curty Pereira R, Rawat A. JMIR Res Protoc. 2026 Sep 25;15:e91534. doi: 10.2196/91534. PMID: 42789402

[Factors influencing human papillomavirus school-based immunization in Alberta: a qualitative inquiry.](#)

Sell H, Malkin J, Allen-Scott L, Toohey A. Can J Public Health. 2026 Sep 24. doi: 10.17269/s41997-026-01250-6. Online ahead of print. PMID: 42786307

[Intranasal Vaccination With Recombinant Human Adenovirus Encoding trans-Sialidase Gene Protects Mice From Lethal Subcutaneous and Oral Trypanosoma cruzi Challenges.](#)

Noronha IH, Wada LN, Rossetto BS, Moraschi BF, Ferreira CP, Santos Santana JK, do Valle RD, Júnior LC GP, Aristeu da Rosa J, Rosa DS, Kim Y, Lopes MF, Ribeiro DA, Gazzinelli RT, Bortoluci KR, Trossini GHG, Silveira ELV, de Vasconcelos JRC. J Infect Dis. 2026 Sep 23;234(3):449-461. doi: 10.1093/infdis/jiag227. PMID: 42028783

[Investigating the association between COVID-19 exposure and fetal and maternal health before public health vaccinations: A retrospective cohort study.](#)

Mohammadi Nasab F, Esmaeilzadeh N, Masoumvand M, Nazarimanesh MA, Gholambareshi P, Vingrys K, Khosravi M. Public Health. 2026 Sep 23;260:106446. doi: 10.1016/j.puhe.2026.106446. Online ahead of print. PMID: 42777297

[Effectiveness of timely hepatitis B birth dose vaccination to prevent mother-to-child transmission in Ethiopia.](#)

Berhe N, Desalegn H, Mengistu H, Birhane D, Kebede B, Maru M, Girma F, Bekele D, Gure T, Yaid H, Abdi S, Shimakawa Y, Johannessen A, Nayagam S; IMPACT-B Study Team; the.Clin Infect Dis. 2026 Sep 24:ciag598. doi: 10.1093/cid/ciag598. Online ahead of print.PMID: 42781776

[COVID-19 vaccine may protect older patients against major adverse CV events.](#)

Roush K.Am J Nurs. 2026 Oct 1;126(10):13. doi: 10.1097/AJN.000000000000388f. Epub 2026 Sep 24.PMID: 42779059

[The intrinsic, instrumental, and symbolic values of sustaining childhood vaccination in conflict settings.](#)

Sabahelzain MM, Razum O, Leask J, Silva DS.Hum Vaccin Immunother. 2026 Dec;22(1):2736323. doi: 10.1080/21645515.2026.2736323. Epub 2026 Sep 30.PMID: 42814974

[Development of a cross-protective subunit cocktail vaccine against diverse serotypes of *Glaesserella parasuis* infection in pigs.](#)

Li F, Gong Y, Li Z, Wang Z, Wu Z, Zhang D, Zhang P, Lu Z, Chu H, Zhang K, Li D, Li N, Lei L.Vet Res. 2026 Sep 27;57(1):172. doi: 10.1186/s13567-026-01846-3.PMID: 42802254

[Expanded prevalence of group 4 capsule expression and its genetic requirements in a broad array of *Shigella* strains.](#)

Brethour BW, Wu T, Guo B, Broussard MD, Rasko DA, Barry EM.mSphere. 2026 Sep 29;11(9):e0035426. doi: 10.1128/msphere.00354-26. Epub 2026 Aug 12.PMID: 42584164

[Clinical and economic benefits of bivalent Respiratory syncytial virus prefusion F \(RSVpreF\) vaccine for prevention of RSV in adults: a cost-effectiveness analysis for Singapore.](#)

Thakkar K, Shajarizadeh A, Gaiind N, Ivkovic L, Balasubramanian G, Kefalogianni R, Zhang J, See KC, Kwa AL, Mendes D.Expert Rev Pharmacoecon Outcomes Res. 2026 Sep 29. doi: 10.1080/14737167.2026.2737558. Online ahead of print.PMID: 42811754

[Booster vaccination with an investigational Lyme disease vaccine in children, adolescents, and adults: a plain language summary.](#)

Wagner L, Messier M, Stark JH, Lamberth E.Expert Rev Vaccines. 2026 Dec;25(1):2722004. doi: 10.1080/14760584.2026.2722004. Epub 2026 Sep 27.PMID: 42802567

[2-Deoxy-D-Glucose in a Human Rhinovirus Challenge Model: a Randomised, Double-blind Placebo-controlled phase 2a clinical trial.](#)

Cnossen VM, Assil S, de Kam ML, Roestenberg M, Gorki AD, Turner RB, Gualdoni GA, Kamerling IMC.Int J Infect Dis. 2026 Sep 25:109144. doi: 10.1016/j.ijid.2026.109144. Online ahead of print.PMID: 42790812

[Accelerated discovery of thermostable mRNA-lipid nanoparticle vaccines using data-efficient AI.](#)

Tian J, Tran KTM, Pogostin BH, Sheridan O, Mursalova S, Lee AH, Liu S, Hamkins J, Antov D, Power AL, Dash ZS, Yun D, Konaković Luković M, Langer RS, Jaklenec A.Nat Biotechnol. 2026 Sep 28. doi: 10.1038/s41587-026-03331-w. Online ahead of print.PMID: 42806112

[Measles, mumps and rubella \(MMR\) vaccination under-recording in primary care in England: a two-stage cluster survey to inform **vaccine** optimisation.](#)

Sanderson K, Robin C, Reynolds R, Hughes G, Campbell CNJ, Beck CR, Oliver I, Edelstein M. *Vaccine*. 2026 Sep 29;93:129216. doi: 10.1016/j.vaccine.2026.129216. Online ahead of print. PMID: 42810172

[Development of a genetically engineered multivalent subunit **vaccine** against "struck", "braxy", lamb dysentery, and enterotoxemia in sheep.](#)

Zhao JH, Ma QL, Wang WB, Gao PC, Qing SR, Tan W, Ma YF, Di N, Li XR, Sun Y, Ran ZG, Zheng FY, Hodnik JJ, Chu YF. *Vaccine*. 2026 Sep 29;93:129207. doi: 10.1016/j.vaccine.2026.129207. Online ahead of print. PMID: 42810174

[Gene electrotransfer for DNA immunotherapy in veterinary oncology: Technical Tutorial Video.](#)

Impellizeri JA, Vigodny A, Sanchez E, Aurisicchio L, Conforti A. *J Am Vet Med Assoc*. 2026 Sep 23:1. doi: 10.2460/javma.26.05.0428. Online ahead of print. PMID: 42777771

[Pediatric Deaths during Measles Outbreak, Jerusalem, Israel, 2025-2026.](#)

Mor Z, Shoob H, Sokolov I, Bucris E, Stein-Zamir C, Tenenbaum A, Megged O, Gordon O. *Emerg Infect Dis*. 2026 Sep 30;32(11). doi: 10.3201/eid3211.261397. Online ahead of print. PMID: 42816773

[Rethinking seasonal COVID-19 vaccination in the endemic era: summer timing, eligibility, and frequency in the United States.](#)

Bubar KM, Park HJ, Bents SJ, Tan ST, Singer BJ, Kelly JD, León TM, Watt J, Schechter R, Lo NC. *medRxiv* [Preprint]. 2026 Sep 25:2026.09.23.26363810. doi: 10.64898/2026.09.23.26363810. PMID: 42818532

[Effectiveness of community-based delivery of mass dog vaccination to prevent rabies: A cluster randomized controlled trial.](#)

Lankester F, Lugelo A, Chagalucha J, Anderson D, Duamor CT, Czupryna A, Lushasi K, Ferguson E, Swai ES, Sambo M, Yoder J, Cleaveland S, Wyke S, Lutege Malinda B, Johnson PCD, Hampson K. *PLoS Negl Trop Dis*. 2026 Sep 25;20(9):e0014704. doi: 10.1371/journal.pntd.0014704. Online ahead of print. PMID: 42789815

[Genetic diversity, pathogenicity, and serological cross-neutralization characteristics of contemporary feline calicivirus isolates from China.](#)

Li N, Aishanjiang K, Tang A, Zhang M, Zhu M, Tan X, Zhu W, Luo D, Zhang D, Li C, Zhu J, Zhu Y, Meng C, Li G, Liu G. *Vet Microbiol*. 2026 Sep 23;322:111229. doi: 10.1016/j.vetmic.2026.111229. Online ahead of print. PMID: 42800431

[One-year antibody kinetics and effectiveness of a BNT162b2 booster after four primary COVID-19 vaccination regimens in Mongolia.](#)

Bazarjav P, Erdene-Ochir T, Sandagdorj A, Enkhtuvshin A, Enkhbayar P, Ganbold S, Baatarsuren N, Sereeter OE, Batmunkh B, Jantsansengee B, Tserendorj C, Dorjderem B, Otgonbayar D, Batjargal A, Badamnachin B, Jigjidsuren N, Janbalganii U, Sereejav E, Enebish O, Janchiv O, Munkhbat B, Baigude H,

Tsolmon B, Ganbold T. Vaccine. 2026 Sep 26;93:129179. doi: 10.1016/j.vaccine.2026.129179. Online ahead of print. PMID: 42800087

[Oncogenic role of human papillomavirus in oral and oropharyngeal cancers: Molecular insights and clinical implications for dental practice.](#)

Desai C, Bhattu BK, Narayan R, Chaudhari K, Thakkar A. J Am Dent Assoc. 2026 Sep 29:S0002-8177(26)00460-5. doi: 10.1016/j.adaj.2026.07.009. Online ahead of print. PMID: 42814067 Review.

[Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAbs induction in SHIV-infected rhesus macaques.](#)

Hogarty MP, Li H, Zhao C, Martella CL, Skelly AN, Habib R, Connell AJ, Bibollet-Ruche F, Liu W, Carey JW, Ayyanathan K, Ding W, Lora J, Park Y, Lewis E, Rando J, Chohan N, Singh A, Wang S, Murphy A, Akeley MJ, Mansouri K, Spence TN, Wiehe KJ, Williams WB, Saunders KO, Wagh K, Seaman MS, Edwards RJ, Haynes BF, Hahn BH, Shaw GM. Proc Natl Acad Sci U S A. 2026 Oct 6;123(40):e2620354123. doi: 10.1073/pnas.2620354123. Epub 2026 Sep 29. PMID: 42809389

[Evaluating an anti-idiotypic derived germline-targeting immunogen designed to elicit VRC01-class precursors in human antibody transgenic mice.](#)

Chhan CB, Wan Y-H, Wilcox-King A, Homad LJ, Aldridge NT, Iureniev R, Stamatatos L, McGuire AT. mSphere. 2026 Sep 29;11(9):e0031726. doi: 10.1128/msphere.00317-26. Epub 2026 Sep 1. PMID: 42678155

[Establishment of an indirect competitive ELISA for detection of antibodies against goose astrovirus genotype 1 based on ORF2 protein.](#)

Yang J, Wei F, Diao Y, Diao Y. J Virol Methods. 2026 Sep 25;347:115473. doi: 10.1016/j.jviromet.2026.115473. Online ahead of print. PMID: 42790820

[Surveillance for severe influenza, COVID-19, and RSV in patients admitted to sentinel Australian hospitals in 2025: the Influenza Complications Alert Network \(FluCAN\) and the Paediatric Active Enhanced Disease Surveillance \(PAEDS\) system.](#)

Morgan H, Dwyer D, Holmes M, Irving L, Rees M, Vincent S, Chiong F, Marr I, Korman T, Bartolo C, Cooley L, Bowler S, Kok J, Runnegar N, Fatovich D, Waterer G, Macartney K, Crawford N, Bellamy K, Carr J, Marshall H, Clark J, Francis J, McMullan B, Britton P, Wood N, Kotsimbos T, Kelly P, Blyth C, Cheng A. Commun Dis Intell (2018). 2026 Sep 29;50. doi: 10.33321/cdi.2026.50.058. PMID: 42805162

[An Adenoviral-Vectored Tp0326 Vaccine Elicits Robust Functional Antibodies to Prevent Treponema pallidum Dissemination in a Rabbit Model.](#)

Jiang Y, Li X, Huang L, Zhang X, Ke W. Adv Sci (Weinh). 2026 Sep 28:e78078. doi: 10.1002/advs.78078. Online ahead of print. PMID: 42806485

[Synthetic PS-III Glycoconjugate Vaccines Based on Solid-Phase Assembled Well-Defined Oligosaccharides Confers Protection against Clostridium difficile.](#)

Chen Y, Liu X, Zhang T, Wang Z, Li Y, Zeng J, Li H, Zong C, Liu Q. *ACS Cent Sci.* 2026 Aug 15;12(9):1429-1438. doi: 10.1021/acscentsci.6c00855. eCollection 2026 Sep 23. PMID: 42799127

[Experimental model of VZV reactivation reveals **vaccine**-induced mechanisms of protection against herpes zoster.](#)

Johnson MJ, Vu T, Ford ES, Jing L, Jordan K, Brown M, Li S, Schedin T, Crotteau M, Canniff J, Bennett A, Weaver N, Laing KJ, Fietze S, Koelle DM, Levin MJ, Weinberg A. *medRxiv [Preprint].* 2026 Sep 25:2026.09.22.26363709. doi: 10.64898/2026.09.22.26363709. PMID: 42818448

[HUMAN PAPILLOMAVIRUS GENOTYPE DISTRIBUTION AMONG ADULT WOMEN IN THE RABAT REGION \(MOROCCO\): A RETROSPECTIVE AND ANALYTICAL STUDY WITH IMPLICATIONS FOR HPV VACCINATION STRATEGIES.](#)

Tagajdid MR, Azelmat S, Goura H, Znady MR, Mansouri D, Abi R, Elannaz H, Elkochri S, Laraqui A, Bouaiti L, Elmengoub F, Ait Bouhou M, Ennibi K, Kouach J, Amine Lahlou I. *Intervirology.* 2026 Sep 23:1. doi: 10.1159/int/adgag002. Online ahead of print. PMID: 42776921

[Development and internal analytical validation of plaque reduction neutralization test for clinical trial application of Kyasanur forest disease virus **vaccine**.](#)

Patil DY, Sahay RR, Shete AM, Mohandas S, Mali D, Pawar N, Lakra R, Marathe H, Gadekar A, Sapkal G, Yadav PD. *Vaccine.* 2026 Sep 27;93:129206. doi: 10.1016/j.vaccine.2026.129206. Online ahead of print. PMID: 42801863

[Combined chlorogenic acid and baicalin supplementation alleviates PRRSV-induced disease by modulating immune responses and gut microbiota in weaned piglets.](#)

He L, Ji S-s, Guan Y, Liu B-L, Huang B-B, Liu T, Xu Z-w, Zhu L. *Microbiol Spectr.* 2026 Sep 28:e0160226. doi: 10.1128/spectrum.01602-26. Online ahead of print. PMID: 42803548

[Wings of access: a cluster RCT on drone-based medical commodity delivery in remote Madagascar.](#)

Tumlinson K, Rabemanantsoa A, Rahantanirina S, Ramanamahefa KJ, Felker-Kantor E, Crapper D, Kioko E, Goland E, Chung SR, Bullington BW, Sylvia S, Templin T. *BMJ Glob Health.* 2026 Sep 29;11(9):e021965. doi: 10.1136/bmjgh-2025-021965. PMID: 42810815

[Using Immunization Data Systems to Track Zero-Dose Children in Bangladesh: Mixed Methods Exploratory Study.](#)

Yunus S, Singh P, John AN, Oliveras E, Uddin MJ, Alam N, Ali MW, Das H, Morgan C. *Online J Public Health Inform.* 2026 Sep 29;18:e88951. doi: 10.2196/88951. PMID: 42809835

[Clinico-epidemiological Profile and Genotype Distribution of Rotavirus Infection Among Children Under Five Years with Acute Gastroenteritis in Garhwal Region of Uttarakhand, India.](#)

Thapliyal A, Jauhari S, Varghese T, Rawat V. *Indian J Med Microbiol.* 2026 Sep 30:101305. doi: 10.1016/j.ijmmb.2026.101305. Online ahead of print. PMID: 42815768

[Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters.](#)

Park H-S, Matsuoka Y, Santos C, Duncan EF, Kaiser JA, Yang L, Luongo C, Liu X, Teng I-T, Kwong PD, Buchholz UJ, Le Nouën C. *J Virol*. 2026 Sep 24:e0093826. doi: 10.1128/jvi.00938-26. Online ahead of print. PMID: 42782150

[Higher Pediatric Influenza Vaccination Coverage in Pooled Northern Hemisphere Countries with Public Access to Live Attenuated Influenza **Vaccine**: Implications for Immunization Policy.](#)

van Beest Holle MRR, Venkatesan S, Enxing J, Alex-Wele C, Jah F, Di Lucchio G. *Infect Dis Ther*. 2026 Sep 26. doi: 10.1007/s40121-026-01452-y. Online ahead of print. PMID: 42799818

[Tomatine Augments T Cell-Mediated Protective Immunity Induced by First-Generation Leishmania Antigen Against Visceral Leishmaniasis.](#)

Saini I, Kaur S. *Immunol Lett*. 2026 Sep 30:107243. doi: 10.1016/j.imlet.2026.107243. Online ahead of print. PMID: 42815693

[Real-world evaluation of 2023-2024 XBB.1.5 mRNA and protein-based COVID-19 **vaccine** reactogenicity from the randomized BEEHIVE trial.](#)

Yoon SK, Phillips AL, Zhao H, Yan F, Chen D, Zhuang Y, Thiese MS, Rowley EAK, McKell J, Yates A, Griffin J, Battan-Wraith S, Campbell R, Fink RV, Williams J, Green N, Allison T, Zhang Y, Ball SW, Toback S, Rousculp MD, Ellsworth GL. *Hum Vaccin Immunother*. 2026 Dec;22(1):2735182. doi: 10.1080/21645515.2026.2735182. Epub 2026 Sep 29. PMID: 42811742

[Pediatric invasive meningococcal disease in Türkiye during the post-pandemic period: increased reported cases and predominance of serogroup B and severity determined by a clinical form in a multicenter hospital-based cohort.](#)

Cakmak Taskin E, Arga G, Arslan BC, Taskin Karacay IE, Genceli M, Erdeniz EH, Kaba O, Avcu G, Kus S, Abaci Capar MC, Kacmaz BB, Alkan G, Yasar Durmus S, Bostan A, Acik AK, Aksoy FD, Celik T, Efendi Kocagoz M, Sener Okur D, Tekin Yilmaz A, Oksuzoglu E, Seyhanli D, Gokay N, Agrali Eroz N, Sinav Utku H, Bayhan C, Ozlu C, Lacinel Gurlevik S, Sutcu M, Kizil MC, Celebi Congur E, Umit Z, Sahin A, Bursal B, Kandemir Gulmez T, Baysal M, Sahin Izci E, Kilinc F, Ersozlu Y, Deniz M, Mete Atasever N, Celik N, Turan C, Cicek A, Korulmaz A, Yahsi A, Yesil E, Kara Aksay A, Bayturan S, Celik U, Ozkaya Parlakay A, Metin Akcan O, Ozdemir H, Yilmaz D, Sahbudak Bal Z, Karbuz A, Emiroglu M, Tural Kara T, Belet N, Kilic O, Oncel S, Tanir Basaranoglu S, Buyukcam A, Akkoc G, Somer A, Dalgic N, Demirhan S, Celik B, Kaleli I, Ersayoglu I, Arslanoglu MO, Oflu AT, Tufan E, Ecevit IZ, Kurugol Z, Dinleyici EC, Tezer H, Kara A, Ciftci E. *Eur J Pediatr*. 2026 Sep 28;185(10):778. doi: 10.1007/s00431-026-07399-z. PMID: 42802197

[Genomic Surveillance of Human Metapneumovirus in the United States, 2010-2025.](#)

Bendall EE, Fitzsimmons WJ, Valvano WD, Truscon R, Self WH, Halasa N, Chappell JD, Zhu Y, Safdar B, Ginde AA, Peltan ID, Gaglani M, Columbus C, Shapiro NI, Gibbs KW, Hager DN, Prekker ME, Mohamed A, Johnson NJ, Steingrub JS, Khan A, Duggal A, Wilson JG, Qadir N, Busse LW, Kwon JH, Exline MC, Vaughn IA, Mosier JM, Harris ES, Dawood FS, Ma KC, Surie D, Monto AS, Martin ET, Luring AS; Investigating

Respiratory Viruses in the Acutely Ill (IVY) Network. *J Infect Dis.* 2026 Sep 23;234(3):e556-e565. doi: 10.1093/infdis/jiag249. PMID: 42089368

[Recoding by N\(1\)-methylpseudouridine guides rational mRNA vaccine design.](#)

Poulis P, Robecchi G, Kurochkina AO, Felletti M, Rodnina MV. *Nat Commun.* 2026 Sep 28;17(1):10029. doi: 10.1038/s41467-026-77796-3. PMID: 42805987

[Heterogeneous Serotype-Specific Immune Responses Following Sequential PCV13-PPSV23 Vaccination in Adults With Type 2 Diabetes Mellitus.](#)

Ramakrishnan SM, Mavupadi AM, Govindan V, Nagaraj G, Rajashekaraiah V, Ravikumar KL. *Hum Immunol.* 2026 Sep 25;87(11):112082. doi: 10.1016/j.humimm.2026.112082. Online ahead of print. PMID: 42790298

[Monoclonal antibodies raised against the Junín virus glycoprotein show broad reactivity and provide protection *in vivo*.](#)

Pena Alzua G, Jan S, Amanat F, Sandoval GA, Sumner CA, Won S, Lara AL, Sinha A, Harmon BN, Allmon EB, Alfson KJ, Goez-Gazi Y, Dutton JW 3rd, Carrion R Jr, Rangarajan S, Kerzic MC, Mitchell CA, Cirimotich CM, Johnson DM, Krammer F. *mBio.* 2026 Sep 25:e0021426. doi: 10.1128/mbio.00214-26. Online ahead of print. PMID: 42788769

[HPV-related head and neck neoplasms in solid organ transplant recipients: a case report highlighting gaps in adult vaccination guidelines.](#)

Wimbish W, Hill-Mak J, Wilson P, Whiteley W, Kale P. *Proc (Bayl Univ Med Cent).* 2026 Sep 23:1-3. doi: 10.1080/08998280.2026.2732437. Online ahead of print. PMID: 42775854

[Immunopeptidomics reveals conserved and abundant Francisella tularensis proteins as immunogenic CD4 T cell antigens in mice.](#)

Laskova P, Porkertova S, Ballek O, Balonova L, Pavloskova J, Neuwirth A, Pavkova I, Fabrik I, Lukac P, Vannucci L, Filipp D, Stulik J, Link M. *PLoS Pathog.* 2026 Sep 29;22(9):e1014597. doi: 10.1371/journal.ppat.1014597. Online ahead of print. PMID: 42809615

[Ocular Safety of Recombinant Zoster Vaccination in Adults Aged 50 Years and Older: A Propensity-Matched Real-World Cohort Study.](#)

Kozlov M, Stratigakis N, Syal S, Gadaria N. *Ocul Immunol Inflamm.* 2026 Sep 29:1-6. doi: 10.1080/09273948.2026.2741723. Online ahead of print. PMID: 42811473

[In Vitro Wrapping of Non-Enveloped Viral Capsids with Lipid Bilayers.](#)

Duran-Meza AL, Villagrana-Escareño MV, Cadena-Nava RD, Ruiz-García J, Knobler CM, Gelbart WM. *Biophys J.* 2026 Sep 30:S0006-3495(26)00659-4. doi: 10.1016/j.bpj.2026.09.029. Online ahead of print. PMID: 42817171

[Improving Vaccination Coverage among Rheumatic Disease Patients by Overcoming Existing Barriers.](#)

Shrivastava SR, Bobhate PS. *Curr Rheumatol Rev.* 2026 Sep 24. doi: 10.2174/0115733971486719260915120020. Online ahead of print. PMID: 42786808

[Sex differences in **vaccine**-induced neuraminidase cross-recognition impact H5N1 dissemination to the lower respiratory tract in mice.](#)

Chaulagain S, Werner AP, Parish MA, Talukdar SN, Yin A, Seibert BA, Zhang T, Liu JA, Schneider C, Coughlan L, Pekosz A, Klein SL. *Vaccine.* 2026 Sep 27;93:129189. doi: 10.1016/j.vaccine.2026.129189. Online ahead of print. PMID: 42801862

[Exploring vaccination adherence and its determinants in kidney transplant recipients: insights from a large italian transplant centre.](#)

Cattelan A, Segala FV, Bragato B, Sasset L, Colombo F, Calandrino L, Martino FK, Cocchio S, Di Bello M, Di Bella C, Nalesso F, Furian L. *Infection.* 2026 Sep 29. doi: 10.1007/s15010-026-02969-7. Online ahead of print. PMID: 42809186

[Novel Liposomal Adjuvants Enhance the Immune Response to Recombinant *Staphylococcus aureus* Antigens in Dairy Heifers.](#)

Cicotello J, Miotti C, Suarez Archilla G, Molineri AI, Aliprandi D, Peña A, Reidel IG, Ricotti S, Zbrun MV, Fraile Wirth L, Signorini ML, Calvino LF, Veaute CMI, Camussone CM. *Vet Med Int.* 2026 Sep 23;2026:7845041. doi: 10.1155/vmi/7845041. eCollection 2026. PMID: 42787394

[Effects of a soluble essential oil additive on inflammatory response, epithelial integrity, and performance of broilers subjected to an experimental infectious bronchitis virus challenge.](#)

Monteiro FA, Cangianelli GH, Costa DR, Pontes KM, Khatlab AS, de Almeida FLA, Miglioranza S, Del Vesco AP, Gasparino E. *Poult Sci.* 2026 Sep 23;105(12):107832. doi: 10.1016/j.psj.2026.107832. Online ahead of print. PMID: 42804826

[Paeoniflorin improved intestinal barrier function and immune homeostasis of broiler chickens challenged with *Eimeria* by modulating gut microbiota and suppressing M1 macrophage-associated inflammatory responses.](#)

Li C, Li S, Tong W, Yan J, Yu M, Ding B, Li P, Guo S. *Poult Sci.* 2026 Sep 27;105(12):107857. doi: 10.1016/j.psj.2026.107857. Online ahead of print. PMID: 42810086

[Trends and disparities in herpes zoster vaccination coverage among US adults with cardiovascular disease.](#)

Ho CY, Hung CT, Huang HY, Wu CH. *Am J Infect Control.* 2026 Sep 30:S0196-6553(26)00730-3. doi: 10.1016/j.ajic.2026.09.018. Online ahead of print. PMID: 42815644

[From human allergen immunotherapy to veterinary prophylactic vaccines: translational potential of Microcrystalline tyrosine as a **vaccine** adjuvant.](#)

Pérez E, Pérez M, Luján L. *Vet Res Commun.* 2026 Sep 29;50(6):604. doi: 10.1007/s11259-026-11546-0. PMID: 42809146

[Bacterial etiology of acute otitis media with spontaneous otorrhea in Spanish children: molecular insights from a multicenter study.](#)

Fernández-Delgado L, Balaguer-Martínez JV, González-Díaz A, Medina-Gómez C, López de Egea G, Esquivel-Ojeda JN, Vera-Estrada M, López-Santiveri A, Pacheco-Navas E, Fernández-Feijoo A, Richter V, Cámara J, Ardanuy C; ETOM-VAC Study Group. *Microbiol Spectr*. 2026 Sep 30:e0229326. doi: 10.1128/spectrum.02293-26. Online ahead of print. PMID: 42813777

[Public availability and completeness of **vaccine** product labeling in China.](#)

Ding Y, Fu M, Ramachandran R, Yin S, Li X, Zhou X, Shi L, Ross JS, Guan X. *Vaccine*. 2026 Sep 29;93:129185. doi: 10.1016/j.vaccine.2026.129185. Online ahead of print. PMID: 42810175

[Evaluation of the real-world protective effect of mumps-containing vaccines among children under 15 years old in Taizhou: A 1:2 matched case-control study.](#)

Liu H, Zhu Z, Liu Y, Wang J, Qian Y, Yu Y, Shen L, Xie Y, Tang W. *PLoS One*. 2026 Sep 28;21(9):e0359417. doi: 10.1371/journal.pone.0359417. eCollection 2026. PMID: 42804452

[Senior High School Nurse-led Education \(SHiNE\) for improving cervical cancer primary prevention among students in Ghana: Pilot cluster non-randomized controlled trial.](#)

Ampofo AG, Mackenzie LJ, Khumalo P, Chittem M, Boyes AW. *Public Health*. 2026 Sep 26;260:106495. doi: 10.1016/j.puhe.2026.106495. Online ahead of print. PMID: 42800380

[Shared evidence, different recommendations: a comparative analysis of Qdenga \(TAK-003\) dengue **vaccine** guidance for travellers across countries.](#)

McGuinness SL, Patel D, Askling HH, Rothe C, Schofield S, Steffen R, Visser LG, Chen LH. *J Travel Med*. 2026 Sep 29;33(6):taag065. doi: 10.1093/jtm/taag065. PMID: 42485451

[Avian metapneumovirus infections in poultry flocks in Poland - molecular evidence for emerging divergence from **vaccine** strains.](#)

Dziadek K, Sajewicz-Krukowska J, Lisowska A, Opolska J, Śmiałek M, Domanska-Blicharz K. *Avian Pathol*. 2026 Sep 23:1-14. doi: 10.1080/03079457.2026.2723912. Online ahead of print. PMID: 42775853

[A large outbreak of acute gastroenteritis caused by rare group C rotavirus in schoolchildren in Yunnan, China: Clinical, epidemiological, and genomic characterization.](#)

Cao Y, Che R, Ma M, Kong L, Jiang S, Li D, Sun X, Gu W. *Virology*. 2026 Sep 26;625:111093. doi: 10.1016/j.virol.2026.111093. Online ahead of print. PMID: 42815046

[Pneumococcal nasopharyngeal carriage, serotype distribution, and vaccination status in hospitalized children in Latvia: A cross-sectional study during the post-PCV13, pre-PCV15/PCV20 transition period.](#)

Cupeca H, Zeltina I, Villerusa A, Savrasova L, Grope I, Mukans M, Kibilds J, Krumina A, Tretjakovs P, Viksna L. *PLoS One*. 2026 Sep 25;21(9):e0359297. doi: 10.1371/journal.pone.0359297. eCollection 2026. PMID: 42789531

[**Vaccine** framing dynamics: Media influence, social media sharing, and public sensemaking during a crisis.](#)

Hubner AY. *Public Underst Sci*. 2026 Sep 28;9636625261477232. doi: 10.1177/09636625261477232. Online ahead of print. PMID: 42803323

[Establishment of a Neonatal Natural Transmission Model for Cytomegalovirus **Vaccine** Development.](#)

Jihad T, Chi XS, He Z, Lee K, Needle E, Loschko J, Goymer J, Wang H, Boigard H, Robertson C, Obregon J, Wilson K, Kanevsky I, Liberator P, Matsuka YV, Walter MR, Jansen KU, Yang X, Dormitzer PR, Swanson KA, Buchkovich NJ. *J Infect Dis.* 2026 Sep 23;234(3):e583-e594. doi: 10.1093/infdis/jiag170. PMID: 41871430

[The Malaria **Vaccine** Implementation Cascade: From introduction to programme performance.](#)

Bouyou-Akotet MK, Mawili-Mboumba DP. *Vaccine.* 2026 Sep 30;93:129190. doi: 10.1016/j.vaccine.2026.129190. Online ahead of print. PMID: 42815120

[Expert Consensus on Controlled Human Infection Studies for Gonorrhoea.](#)

Hodgson SH, McCarthy JS, Duncan JA, Williams E, McLaughlin S, Alaimo C, Davis P, Delany I, Douglas AD, Gray-Owen SD, Gorringer A, Harrison OB, Jamrozik E, MacLennan C, Moxon R, O'Brien S, Pizza M, Pollock GL, Ram S, Seib KL, Vanderslott S, Vichos I, Williamson DA, Wolanin K, Zimmer-Harwood P, Chow EPF. *J Infect Dis.* 2026 Sep 26;jiag486. doi: 10.1093/infdis/jiag486. Online ahead of print. PMID: 42800054

[The 2026 Bundibugyo outbreak exposes critical gaps in Ebola **vaccine** preparedness beyond Zaire and Sudan.](#)

Juyal D, Thaledi S, Pal S. *J Travel Med.* 2026 Sep 29;33(6):taag067. doi: 10.1093/jtm/taag067. PMID: 42497090

[Pilot evaluation of a clinical decision support system package to facilitate proactive HPV vaccination in community pharmacies.](#)

Shah PD, Schwartz J, Bacci JL, Calo WA, Li L, Glascock M, Ndugulile M, Watabayashi K. *J Am Pharm Assoc (2003).* 2026 Sep 29:103533. doi: 10.1016/j.japh.2026.103533. Online ahead of print. PMID: 42810513

[The impact of free influenza vaccination schemes on **vaccine** uptake among older adults in Europe, 2019-2020.](#)

Juet A. *Eur J Health Econ.* 2026 Sep 30. doi: 10.1007/s10198-026-01983-8. Online ahead of print. PMID: 42814236

[Innate immune sensing of Plasmodium sporozoite cell traversal drives protective T cell responses.](#)

Pohl KG, Gao X, McGowan J, Mukherjee P, Le S, Carreira P, Ngo C, Sutton HJ, Brumhard S, Hiller A, Kelly HG, Liow L, Lo A, Henze L, Loyal L, Amino R, Man SM, Beattie L, Sander LE, Cockburn IA. *Nat Microbiol.* 2026 Sep 30. doi: 10.1038/s41564-026-02460-x. Online ahead of print. PMID: 42816580

[Mass-standardised quantitative biophotonic assay for profiling the SARS-CoV-2 spike IgG response in recovery and vaccination cohorts.](#)

James-Pemberton PH, Helliwell MW, Olkhov RV, Kohli S, Westlake AC, Farrar BM, Shaw AM. *Analyst.* 2026 Sep 30. doi: 10.1039/d6an00659k. Online ahead of print. PMID: 42813529

[Seroprevalence of Japanese encephalitis virus and other flavivirus-specific antibodies among Australian blood donors following a novel epidemic spread of Japanese encephalitis virus: a cross-sectional study.](#)

Koirala A, Winkler NE, Prasad SA, Hirani R, Baker J, Hueston L, O'Sullivan M, Stepien S, Hoad V, Kok J, Gosbell IB, Kaur G, Jackson J, Snelling TL, Dwyer DE, Irving DO, Macartney K. *BMJ Open*. 2026 Sep 30;16(9):e117510. doi: 10.1136/bmjopen-2026-117510.PMID: 42816093

[SwiVirScan, a high-throughput platform for profiling antibodies to swine-associated viruses, reveals extensive viral exposure histories in pigs.](#)

Zhang Q, Dong J, Guo P, Wang W, Zhang X, Pei S, Dong Z, Qian P, Tao P. *Virol Sin*. 2026 Sep 30:S1995-820X(26)00175-6. doi: 10.1016/j.virs.2026.09.013. Online ahead of print.PMID: 42815855

[Hajj and Umrah in the era of evolving meningococcal risk: Closing implementation gaps in vaccine verification and risk communication.](#)

Assiri AM, Azhar EI. *J Infect Public Health*. 2026 Sep 26;19(11):103376. doi: 10.1016/j.jiph.2026.103376. Online ahead of print.PMID: 42805009

[In vivo-edited CCR7⁺IL-7⁺ DCs reverse T cell exhaustion by promoting T memory stem cell differentiation.](#)

Fu S, Ma Q, Gao S, Xia Z, Mu W, Liang S, Yuan S, Liu J, Xia Y, Liu X, Han L, Liu Y, Zhang N. *Cell Rep Med*. 2026 Sep 30:103086. doi: 10.1016/j.xcrm.2026.103086. Online ahead of print.PMID: 42815468

[Tuning intracellular immunity by Nodamura virus B2 protein enhances self-amplifying RNA activity.](#)

Sanchez-David RY, Nemegeer J, Le HD, Žusinaite E, Spiga L, Gonçalves A, Tregoning JS, Merits A, Maillard PV. *Nat Commun*. 2026 Sep 28;17(1):10028. doi: 10.1038/s41467-026-77816-2.PMID: 42805992

[Summary of National Surveillance Data on Vaccine Preventable Diseases in Australia, 2019-2022.](#)

Jackson J, Sonneveld N, Wang H, Hossain F, Dey A, Lambert S, Beard F. *Commun Dis Intell (2018)*. 2026 Sep 29;50. doi: 10.33321/cdi.2026.50.040.PMID: 42805160

[Host cell traversal by Plasmodium parasites drives sterilizing T cell-mediated immunity following immunization.](#)

Rodrigues A, Mendes AM, Gonçalves R, Nunes-Cabaço H, Marques S, Valente-Leal N, Gomes da Costa D, Ferreira C, Veldhoen M, Prudêncio M, Mota MM, Chora ÂF. *Nat Microbiol*. 2026 Sep 30. doi: 10.1038/s41564-026-02477-2. Online ahead of print.PMID: 42816581

[Beyond disease prevention: rotavirus vaccine rollout and child stunting in Tanzania.](#)

Mwaseba SL, Burger R, von Fintel D. *Vaccine*. 2026 Sep 28;93:129210. doi: 10.1016/j.vaccine.2026.129210. Online ahead of print.PMID: 42805052

[Transient ultrastructural remodeling of the open canalicular system and α-granules is associated with endothelial responses after BNT162b2 vaccination in healthy volunteers.](#)

Carlini V, Trabucchi E, Santo N, Lattuada N, Saccucci S, Allevi R, Rispoli F, Bianchi B, Longhi E, Granizo MBM, D'Anzeo M, Berra C, Naselli A, Settembrini A, Tagliabue E, Vianello E, Dozio E, Romanelli MC, Pontiroli AE, Bolognesi M, La Sala L. *Biomed Pharmacother*. 2026 Sep 29;204:119961. doi: 10.1016/j.biopha.2026.119961. Online ahead of print.PMID: 42809927

[Community Pharmacists' Attitudes and Experiences Regarding the Promotion of Vaccinations in Japan.](#)

Iwata H, Kiriara T, Kobayashi N, Nakamura Y, Koike T, Yamaura K. *Keio J Med.* 2026 Sep 25;75(3):55-62. doi: 10.2302/kjm.2025-0007-OA. Epub 2026 Feb 13. PMID: 41692432

[Nationwide registry-based analysis of rabies exposures in Iran: Epidemiological patterns and post-exposure prophylaxis adherence.](#)

Babae E, Yousefzadeh Eshkouri A, Eshrati B, Nojomi M, Shirzadi MR, Asadi-Aliabadi M, Moosazadeh A. *PLoS Negl Trop Dis.* 2026 Sep 30;20(9):e0014751. doi: 10.1371/journal.pntd.0014751. eCollection 2026 Sep. PMID: 42814726

[Trust in government institutions and influenza **vaccine** acceptance among U.S. adults.](#)

Hyder S, Melchinger H, Malik F, Kuppalli K, Tracy M, Omer SB, Malik AA. *Vaccine.* 2026 Sep 29;93:129212. doi: 10.1016/j.vaccine.2026.129212. Online ahead of print. PMID: 42810171

[Native elution immunoaffinity chromatography for the efficient purification of vesicular stomatitis virus.](#)

Gulan P, Forčić D, Ravlić S, Lukačević SM, Kurtović T, Halassy B, Štimac A. *J Chromatogr A.* 2026 Sep 27;1785:467294. doi: 10.1016/j.chroma.2026.467294. Epub 2026 Jul 23. PMID: 42531822

[Information provision about cost coverage and parental HPV vaccination intentions: A randomized survey experiment in the Czech Republic.](#)

Staněk R, Krčál O. *Health Policy.* 2026 Sep 23;175:105772. doi: 10.1016/j.healthpol.2026.105772. Online ahead of print. PMID: 42815234

[Corrigendum to "Development and evaluation of a multi-epitope subunit **vaccine** against Salmonella Enteritidis infection" \[Poultry Science, Volume 105, Issue 11, November 2026, Article 107636\].](#)

Zhao Y, Li G, Li YA, Li Q, Shi H. *Poult Sci.* 2026 Sep 29;105(12):107845. doi: 10.1016/j.psj.2026.107845. Online ahead of print. PMID: 42810084

[Workplace Health Promotion Practices in Brazilian Companies: Initial Findings From the Brazilian Version of the CDC Worksite Health ScoreCard.](#)

Silva-Junior JS, Freitas LVL, Farinha PH, Roviello VD, Gallasch CH, Pedro TB, Barcelos RC, Ogata AJN. *J Occup Environ Med.* 2026 Sep 25. doi: 10.1097/JOM.0000000000003893. Online ahead of print. PMID: 42789937

[Human memory CD4 + T cells recognize non-infected macrophage bystanders exposed to *Mycobacterium tuberculosis* -infected cells.](#)

Suzart VG, Schauner R, Reba SM, Gail DP, Swarbrick G, Lewinsohn DM, Lewinsohn DA, Lepe B, Bryson BD, Behar SM, Sasseti CM, Freeman ML, Boom WH, Harding C, Carpenter SM. *bioRxiv [Preprint].* 2026 Sep 24:2026.09.19.752467. doi: 10.64898/2026.09.19.752467. PMID: 42818070

[Genetic variation in HLA, IGKV, and HHEX loci influences mRNA **vaccine**-induced humoral protection against COVID-19.](#)

Puzek B, Wratil PR, Janke C, Le Thi TG, Rubio-Acero R, Lupoli G, Schoof IC, Stern M, Zhelyazkova A, Rech J, Choukér A, Koletzko B, Wieser A, Török HP, Castelletti N, Keppler OT, Geldmacher C, Hornung V, Zeggini E, Adorjan K, Hoelscher M, Koletzko S, Kim-Hellmuth S. *Cell Rep.* 2026 Sep 29;45(10):117981. doi: 10.1016/j.celrep.2026.117981. Online ahead of print. PMID: 42814572

[Immune Checkpoint Inhibitor as a Fifth Component of Lipid Nanoparticles Enables Lymph Node-Targeting and Augments mRNA **Vaccine** Efficacy.](#)

Ha M, Kim J, Kim S, Naidu GS, Cho S, Yong SB. *Adv Sci (Weinh).* 2026 Sep 27:e77923. doi: 10.1002/advs.77923. Online ahead of print. PMID: 42801710

[Cost-utility analysis of pre-exposure prophylaxis rabies **vaccine** in 5-year-old children in Thailand.](#)

Soopairin S, Luksameesate P, Arthonchaikul N, Punrin S, Tantawichien T, Taychakhoonavudh S. *BMJ Glob Health.* 2026 Sep 25;11(9):e022168. doi: 10.1136/bmjgh-2025-022168. PMID: 42791044

[Knowledge and attitudes of medical students about human papillomavirus \(HPV\) and HPV **vaccine**: A cross-sectional survey in Inner Mongolia, China.](#)

Zhou X, Yao D, Li T, Guo Z, Jiang M, Sude B, Zhou YH, Meng H. *Hum Vaccin Immunother.* 2026 Dec;22(1):2738975. doi: 10.1080/21645515.2026.2738975. Epub 2026 Sep 27. PMID: 42802652

[Hand, Foot, and Mouth Disease Surveillance in Anhui, After Introduction of the Enterovirus 71 **Vaccine** and During the COVID-19 Pandemic: Ecological Interrupted Time Series Study.](#)

Li K, Wu J, Ma W, Chen T, Zenghuang Y, Rui J, Zhao Z, Wu J, Chen T. *JMIR Public Health Surveill.* 2026 Sep 24;12:e99663. doi: 10.2196/99663. PMID: 42785728

[Hepatitis B Vaccination for Liver Transplant Recipients in the United States: A National Cohort Study.](#)

Shi MA, Han J, Albahra R, Machicao MF, Chiu CY, Khaderi S, Hernaez R, Kanwal F, El-Serag HB, Cholankeril G, Lee TH. *Clin Infect Dis.* 2026 Sep 29:ciag585. doi: 10.1093/cid/ciag585. Online ahead of print. PMID: 42806829

[Mpox **Vaccine** Acceptance Among Health Care Workers in Central Asia: The Role of COVID-19 Experience.](#)

Bolatov A. *Disaster Med Public Health Prep.* 2026 Sep 29;20:e167. doi: 10.1017/dmp.2026.10447. PMID: 42808141

[Estimating age-stratified measles susceptibility using the screening method: an example from 2018-21 measles resurgence in Brazil.](#)

Cammarota D, Coutinho RM, Kraenkel RA. *Trans R Soc Trop Med Hyg.* 2026 Sep 29:trag116. doi: 10.1093/trstmh/trag116. Online ahead of print. PMID: 42808841

[Safety and immunogenicity of a recombinant vesicular stomatitis virus-based Sudan virus **vaccine** in adults in the USA: a single-blind, first-in-human, dose-escalation phase 1 clinical trial.](#)

Laufer DS, Marini A, Philiponis V, Fast PE, Zaric M, Sigei F, Bromell RV, Fernandez N, Hayes PJ, Yun H, Varma R, Pindolia H, Amini F, Hunt D, Boutwell A, Morrow G, Cooper CL, Parks CL, Meller M, Talasila S, Sayeed E, Halpern J, Kennedy A, Mugo C, Chandel S, Mabushi AF, Park H, Chu L, Denham DS, Kilianski A,

Malkevich N, Feinberg MB, Gupta SB. *Lancet Microbe*. 2026 Sep 23;101492. doi: 10.1016/j.lanmic.2026.101492. Online ahead of print. PMID: 42777745

[Real-World Evaluation of Recombinant Zoster **Vaccine** Uptake and Outcomes in Solid Organ Transplant Recipients: A Retrospective Cohort Study.](#)

Rendell SR, Farrell K, Regan DJ, Maurer R, Tullius SG, Azzi JR, Elias N, Riella LV, Rutherford AE, Shah SA, Bethea ED, Coppolino A 3rd, Langer NB, Keller BC, Michel E, Lewis GD, Itoh A, Givertz MM, Irwin L, Barnabas RV, Baden LR, Woolley AE. *Am J Transplant*. 2026 Sep 28:S1600-6135(26)02794-2. doi: 10.1016/j.ajt.2026.09.033. Online ahead of print. PMID: 42805436

[HPV knowledge, awareness, and **vaccine** beliefs among women attending gynecological care in Türkiye: implications for cervical cancer prevention.](#)

Efe Camili F, Aksu S. *Infect Agent Cancer*. 2026 Sep 25;21(1):63. doi: 10.1186/s13027-026-00803-1. PMID: 42816896

[Effect of HPV **Vaccine** Introduction at 9-10 years: A Randomized Clinical Trial.](#)

Kempe A, Vangala S, Albertin C, O'Leary S, Beaty B, Saville AW, Gurfinkel D, Humiston S, Nagel S, Singh J, Golden C, Woo H, Clark E, Szilagyi PG. *medRxiv [Preprint]*. 2026 Sep 27:2026.09.24.26363898. doi: 10.64898/2026.09.24.26363898. PMID: 42818472

[Evaluation of inactivated and live attenuated, tetravalent dengue **vaccine** prime-boost strategies in a randomized, open-label, phase I study: implications for understanding immune correlates of protection.](#)

Koren M, Pollett S, Akerele K, Lee C, Mills K, Moon JE, Keiser PB, Hutter J, Hamer M, Curley JM, Copeland NK, Thomas SJ, McCracken MK, Hang J, Jarman RG, Currier JR, Friberg H, Gromowski GD. *mSphere*. 2026 Sep 29;11(9):e0049726. doi: 10.1128/msphere.00497-26. Epub 2026 Aug 31. PMID: 42671174

[Fatal Disseminated Herpes Zoster With Varicella-Zoster Virus Pneumonia Despite Two-Dose Recombinant Zoster Vaccination in an Immunosuppressed Patient.](#)

Konishi K, Abe F, Wakabayashi H, Tanaka E, Sakai D, Nishida A, Kaneko K, Higuchi T. *J Dermatol*. 2026 Sep 27. doi: 10.1111/1346-8138.70510. Online ahead of print. PMID: 42802101

[Self-Assembled PEDV Virus-Like Particle Nanovaccines Elicit Potent Neutralizing Antibodies and Confer Full Protection in Piglets.](#)

Jiang F, Bai L, Zhang Y, Song Y, Muhammad Z, Yang F, Yang J, Wang H. *ACS Appl Mater Interfaces*. 2026 Sep 23. doi: 10.1021/acsami.6c12664. Online ahead of print. PMID: 42771794

[Identification of a novel linear B-cell epitope in the N-terminus of varicella-zoster virus glycoprotein B.](#)

Chen Y, Yang M, Liu H, Liu E, Zhou J, Zhu X, Wu S, Qi Y, Wang A. *Arch Microbiol*. 2026 Sep 26;208(12):665. doi: 10.1007/s00203-026-05013-2. PMID: 42799870

[Urgent need to update SARS-CoV-2 mRNA **vaccine** product monograph information in Canada for pregnant or lactating people.](#)

Manca TA, Top KA. *CMAJ*. 2026 Sep 27;198(33):E1303-E1304. doi: 10.1503/cmaj.260860. PMID: 42805632

[Corrigendum to 'Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease' \[Vaccine 31 \(2013\) 3065-3071\].](#)

Sempere L, Almenta I, Barrenengoa J, Gutiérrez A, Villanueva CO, de-Madaria E, García-Román V, Sánchez-Payá J. *Vaccine*. 2026 Sep 28;129140. doi: 10.1016/j.vaccine.2026.129140. Online ahead of print. PMID: 42805842

[Intention to Receive COVID-19 Vaccination and Its Associated Factors Among Community in Motta Town, North West Ethiopia, 2022: Application of Theory of Planned Behavior.](#)

Getachew A, Wasihun Y, Fentahun N, Lakew G. *Public Health Chall*. 2026 Sep 23;5(3):e70383. doi: 10.1002/puh2.70383. eCollection 2026 Sep. PMID: 42781672

[Caregiver knowledge and Attitudes toward Human Papillomavirus Vaccination among adolescent girls living with HIV in Sierra Leone: A health facility-based cross-sectional study.](#)

Jiba DF, Baldeh M, Turay P, Kanu S, Kamara MN, Farma LML, Barrie U, Awonuga WO, Baio MM, Sesay D, Shehab D, Sinnah R, Namanga ES, Johnson PMD, Lakoh S, Dykens JA. *medRxiv* [Preprint]. 2026 Sep 23:2026.09.21.26363609. doi: 10.64898/2026.09.21.26363609. PMID: 42818422

[Fish immunization by duckweed biomass accumulating recombinant cyprinid herpesvirus 3 antigens induces specific immune response.](#)

Kishchenko O, Peterson A, Adamek M, Schroers VJ, Piačková V, Korytář T, Cuacos M, Giritch A, Kuhlmann M, Schubert I, Nagel M. *N Biotechnol*. 2026 Sep 25;94:272-282. doi: 10.1016/j.nbt.2026.06.011. Epub 2026 Jul 1. PMID: 42385953

[Human Papillomavirus \(HPV\) and Cervical Cancer: An Exploratory Systematic Review of Heterogeneous Evidence on Epidemiology, Vaccination, Screening, and Molecular Advances.](#)

Shoarishoar SS, Seifollahi Marbini M. *Cancer Invest*. 2026 Sep 29:1-19. doi: 10.1080/07357907.2026.2740708. Online ahead of print. PMID: 42811780

[The high protection of a novel chemo-attenuated sporozoite vaccine requires IL-15-mediated liver CD8\(+\) tissue-resident memory T-cell responses.](#)

Tan N, Zhu C, Li T, Su S, Jiao S, Gao Y, Ding Y, Liu T, Xu W. *mBio*. 2026 Sep 24:e0113126. doi: 10.1128/mbio.01131-26. Online ahead of print. PMID: 42782159

[Epithelial interferon-γ responsiveness shapes chemokine induction and clinical outcomes in herpes simplex virus infection.](#)

Zimenko A, Hayman I, Fong Y, Monroe LD, Mills MG, Greninger A, Johnston C, Corey L, Zhu J. *PLoS Pathog*. 2026 Sep 30;22(9):e1014612. doi: 10.1371/journal.ppat.1014612. Online ahead of print. PMID: 42814769

[Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids.](#)

Kastenschmidt JM, Sureshchandra S, Jain A, Hernandez-Davies JE, de Assis R, Wagoner ZW, Sorn AM, Mitul MT, Benchorin AI, Levendosky E, Ahuja G, Zhong Q, Trask D, Boeckmann J, Nakajima R, Jasinskas A,

Saligrama N, Davies DH, Wagar LE. Immunity. 2026 Sep 30:S1074-7613(26)00399-7. doi: 10.1016/j.immuni.2026.09.023. Online ahead of print. PMID: 42815462

[Preserving vaccination across the Pacific and beyond: the Asian route of the Royal Philanthropic **Vaccine** Expedition.](#)

Tuells J.J Travel Med. 2026 Sep 29;33(6):taag076. doi: 10.1093/jtm/taag076. PMID: 42644456

[Corrigendum to "Comprehensive characterization of multivalent mRNA vaccines functionality by flow cytometry and mass spectrometry" \[**Vaccine** 74 \(2026\) 128180\].](#)

Willemin T, Guinchard F, Marmey J, Chareyre A, Aguesse A, Peronin S, Bouhired M, Malburet C, Talaga P, Abachin E, Fertier-Prizzon S. Vaccine. 2026 Sep 30:129184. doi: 10.1016/j.vaccine.2026.129184. Online ahead of print. PMID: 42816285

[Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.](#)

Liao W, Shao F, Wang S, Wang Y, Chen X, Zhang Y, Zhang Z, Zai X, Yang Y, Yin Y, Wang Y, Zhang J, Wang J, Xu J. Signal Transduct Target Ther. 2026 Sep 23;11(1):404. doi: 10.1038/s41392-026-02787-1. PMID: 42778529

[Knowledge and attitudes of medical students about human papillomavirus \(HPV\) and HPV **vaccine**: A cross-sectional survey in Inner Mongolia, China.](#)

Zhou X, Yao D, Li T, Guo Z, Jiang M, Sude B, Zhou YH, Meng H. Hum Vaccin Immunother. 2026 Dec;22(1):2738975. doi: 10.1080/21645515.2026.2738975. Epub 2026 Sep 27. PMID: 42802652

[Correction to: Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV **Vaccine** Administered 24 Months Following a Primary Dose in Adults 60 Years of Age.](#)

[No authors listed] J Infect Dis. 2026 Sep 23;234(3):e750. doi: 10.1093/infdis/jiag422. PMID: 42599736

[From human allergen immunotherapy to veterinary prophylactic vaccines: translational potential of Microcrystalline tyrosine as a **vaccine** adjuvant.](#)

Pérez E, Pérez M, Luján L. Vet Res Commun. 2026 Sep 29;50(6):604. doi: 10.1007/s11259-026-11546-0. PMID: 42809146

[Recombinant GI-19 infectious bronchitis virus induction of humoral immunosuppression with reduced HI antibody response following Newcastle disease virus vaccination and bursal cell apoptosis.](#)

Wang C, Zhang W, Hou B. Vet Res. 2026 Sep 24;57(1):170. doi: 10.1186/s13567-026-01839-2. PMID: 42786487

[Generation and characterization of a PRRSV-2 DIVA marker virus by deletion of a novel epitope in the nucleocapsid protein.](#)

Sun J, Wang J, Li K, Wei D, Li J, Sun P, Li D, Li P, Cao Y, Tang L, Lu Z, Zhang J. J Virol. 2026 Sep 24:e0125926. doi: 10.1128/jvi.01259-26. Online ahead of print. PMID: 42782146

[Cell-Mediated Immunity of mRNA-1283 **Vaccine** Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies.](#)

Frey AW, Budigi Y, Girard B, Santos G, Harmon C, Hasan MM, McGrath S, Paila YD, Carfi A, Edwards D, Wahid R, Das R, Chalkias S. *J Infect Dis.* 2026 Sep 23;234(3):e522-e530. doi: 10.1093/infdis/jiag248.PMID: 42240400

[Summary of National Surveillance Data on **Vaccine** Preventable Diseases in Australia, 2019-2022.](#)

Jackson J, Sonneveld N, Wang H, Hossain F, Dey A, Lambert S, Beard F. *Commun Dis Intell* (2018). 2026 Sep 29;50. doi: 10.33321/cdi.2026.50.040.PMID: 42805160

[Epstein-Barr virus gp350 neutralizing epitopes define distinct sites of vulnerability.](#)

Zhao GX, Li PL, Yuan BY, Luo QH, Li T, Ma HY, Huang RJ, Bu GL, Xie C, Wu PH, Zhou H, Du WT, Wang J, Fang DJ, Zeng MS, Dong HH, Feng GK, Zhong Q, Sun C. *Cell Rep.* 2026 Sep 26;45(10):118072. doi: 10.1016/j.celrep.2026.118072. Online ahead of print.PMID: 42800025

[Preparation and Immunological Efficacy Assessment of an Oral Nanovaccine with CyHV-3 ORF57 Recombinant Protein.](#)

Ouyang P, Zhu Y, Zhang N, Chen F, Li X, Liu B, Chen D, Huang X, Song K, Geng Y. *Fish Shellfish Immunol.* 2026 Sep 29;111743. doi: 10.1016/j.fsi.2026.111743. Online ahead of print.PMID: 42810467

Patentes registradas en Patentscope

Estrategia de búsqueda: (*Vaccine*) AND DP:([23.09.2026 TO 30.09.2026]) as the publication date 47 records.

1. [WO/2026/198303](#) THERAPEUTIC HEPATITIS B **VACCINE** COMPOSITION AND METHOD OF USE THEREOF

WO - 24.09.2026

Clasificación Internacional [A61K 39/29](#)Nº de solicitud PCT/US2026/018743 Solicitante DNA PLUS VACCINES COMPANY LIMITED Inventor/a LU, Shan

A method for introducing an antibody response against HBsAg in a subject with CHB, comprising the steps of: (1) administering to the subject an effective amount of a prime **vaccine**, wherein the prime **vaccine** comprises one or more polynucleotide construct (e.g., a DNA construct, a mRNA construct, or a viral vector) encoding one or more forms of HBsAg; and (2) administering to the subject an effective amount of a boost **vaccine**, wherein the booster **vaccine** comprises one or more commercially available recombinant protein Hepatitis B **Vaccine**, wherein the boost **vaccine** is administered after the administration of the prime **vaccine**.

2. [WO/2026/193816](#) MAF **VACCINE**, PREPARATION METHOD THEREFOR, AND USE THEREOF

WO - 24.09.2026

Clasificación Internacional [A61K 39/00](#)Nº de solicitud PCT/CN2025/083718 Solicitante SICHUAN UNIVERSITY Inventor/a WEI, Xiawei

Provided in the present invention is an MAF vaccine. Using an MAF protein as a model antigen, the MAF vaccine is an MAF adenovirus vaccine constructed on the basis of an adenovirus vector and/or a peptide fragment vaccine encapsulated with an auxiliary component. The gene sequence of the model antigen comprises the amino acid sequence set forth in SEQ ID NO: 1. Also provided in the present invention are a preparation method for the MAF vaccine and use thereof in the preparation of a drug for preventing and/or treating fibrotic interstitial lung disease.

3. 20260284177 HETEROLOGOUS PRIME BOOST VACCINE COMPOSITIONS AND METHODS OF USE
US - 24.09.2026

Clasificación Internacional A61K 39/215 N° de solicitud 18846711 Solicitante Generation Bio Co. Inventor/a Phillip Samayoa

The application describes methods of inducing an immune response in a subject, comprising administering a prime-boost vaccine, wherein the priming vaccine comprises DNA (e.g., ceDNA) encoding a first peptide, and the boosting vaccine comprises (i) a ribonucleic acid (RNA), or (ii) a second peptide. Also provided are vaccine regimens, comprising a priming vaccine comprising DNA, wherein the DNA encodes a first peptide; and a boosting vaccine comprising (i) a ribonucleic acid (RNA), or (ii) a second peptide, wherein the RNA encodes the second peptide.

4. 20260286438 BIOMARKER COMPOSITION FOR PREDICTING EFFICACY OF TUBERCULOSIS VACCINE COMPRISING NKG7 AND USE THEREOF

US - 24.09.2026

Clasificación Internacional C12Q 1/6883 N° de solicitud 19435972 Solicitante INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY Inventor/a Sang Jun HA

The present invention relates to a method for predicting efficacy of a tuberculosis vaccine comprising NKG7, in which the NKG7 mediates an immune response induced by administration of a tuberculosis vaccine and exhibits increased expression levels in activated immune cells. Accordingly, by measuring expression levels of a NKG7 protein or a gene encoding the same, prediction accuracy for efficacy or protective immunity of a tuberculosis vaccine can be increased, thereby enabling rapid evaluation of vaccine efficacy, and thus the method can be usefully used in the medical field related to tuberculosis vaccines.

5. 20260286434 BIOMARKER COMPOSITION FOR PREDICTING EFFICACY OF TUBERCULOSIS VACCINE COMPRISING CCL5 AND USE THEREOF

US - 24.09.2026

Clasificación Internacional C12Q 1/6876 N° de solicitud 19436015 Solicitante INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY Inventor/a Sang Jun HA

The present invention relates to a method for predicting efficacy of a tuberculosis vaccine comprising CCL5, in which the CCL5 mediates an immune response induced by administration of a tuberculosis vaccine and exhibits increased expression levels in activated immune cells. Accordingly, by measuring expression levels of a CCL5 protein or a gene encoding the same, prediction accuracy for efficacy or protective immunity of a tuberculosis vaccine can be increased, thereby enabling rapid evaluation of vaccine efficacy, and thus the method can be usefully used in the medical field related to tuberculosis vaccines.

6. 2645265 METHOD FOR TESTING IN-VITRO BACTERICIDAL FUNCTION OF TYPHOID **VACCINE** IMMUNE SERUM

GB - 23.09.2026

Clasificación Internacional C12Q 1/18Nº de solicitud 202522902 Solicitante LANZHOU INST OF BIOLOGICAL PRODUCTS CO LTD Inventor/a HAOFENG REN

Provided is a method for testing the in-vitro bactericidal function of a typhoid **vaccine** immune serum, comprising: testing the in-vitro bactericidal function of a typhoid **vaccine** immune serum against Salmonella typhi bacteria by means of an opsonophagocytic killing assay, wherein when the phagocytic killing step of the opsonophagocytic killing assay is completed, the Salmonella typhi bacteria having undergone the phagocytic killing step are cultured at the pH of 7.5-9.5. The opsonophagocytic killing assay is applied to Gram-negative Salmonella Typhi bacteria for the first time, and the in-vitro bactericidal levels of typhoid **vaccine** immune serums are effectively and accurately evaluated.

7. 4809075 ONKOLYTISCHES VACCINIA-VIRUS

EP - 23.09.2026

Clasificación Internacional C12N 7/01Nº de solicitud 24887192 Solicitante GENVIRA BIOSCIENCES INC Inventor/a WANG JIAHU

The present invention provides genetically modified vaccinia virus which may be employed as an oncolytic viral vector, wherein the genetically modified vaccinia virus comprises a nucleic acid molecule encoding a modified matrix protein from a vesicular stomatitis virus and wherein the genetically modified vaccinia virus is fusogenic.

8. 20260285920 HORN FLY **VACCINE** COMPOSITIONS AND METHODS OF MAKING SAME

US - 24.09.2026

Clasificación Internacional C07K 14/435Nº de solicitud 19252982 Solicitante TNG Pharmaceuticals, Inc. Inventor/a Kent R. Van Kampen

Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are **vaccine** compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or **vaccine** compositions. Further disclosed are methods for the preparation of a fusion protein composition.

9. 20260284186 BIOLOGICAL RESPONSE MODIFIERS FOR THE TREATMENT OF SUBJECTS WITH UNDERPERFORMING IMMUNE SYSTEMS AND COMPOSITIONS THEREOF

US - 24.09.2026

Clasificación Internacional A61K 39/39Nº de solicitud 19168627 Solicitante HELMHOLTZ ZENTRUM FÜR INFektionsFORSCHUNG GMBH Inventor/a Julio Cesar Aguilar RUBIDO

In the present invention, the cyclic-di-nucleotides or their compositions are used as biological response modifiers to improve the immune response of subject with underperforming immune systems with low/non-responsiveness to **vaccine** antigens or underperforming immune response to pathogens. The formulations of the present invention are capable of modifying the biological response in the way of abrogating the non-responsiveness resulting in the development of a high avidity immune response preventing the disease caused by infectious agents, in particular from viruses, with the capacity to evade the mechanisms of immune surveillance and consequently suppress the induction of a high avidity and effective adaptive response. The present invention also comprises the formulations of cyclic di-nucleotides, which may be administered alone, in combination with other biological response modifiers or in **vaccine** formulations with antigens. The proposed invention also includes the method of preventing or treating acute respiratory infections, preventing the severity of the disease and blocking transmission by inducing an immune response at the entry site (nasopharyngeal mucosa), preventing or reducing person-to-person pathogen/virus transmission in pre-emptive **vaccine** formulations as well as in formulations used for pre-/post exposure prophylaxis of acute respiratory infections.

10. 4810057 RSV-IMPFFSTOFFZUSAMMENSETZUNG, VERFAHREN UND VERWENDUNG DAVON

EP - 23.09.2026

Clasificación Internacional A61K 39/155Nº de solicitud 24890742Solicitante SICHUAN CLOVER BIOPHARMACEUTICALS INCInventor/a LIANG JOSHUA

The present invention provides a recombinant peptide and an immunogenic composition comprising the recombinant peptide. The recombinant peptide comprises a soluble respiratory syncytial virus (RSV) antigen, the soluble RSV antigen comprises a recombinant F protein peptide, and the soluble RSV antigen is linked to the C-terminal part of collagen by means of in-frame fusion to form a disulfide-connected trimeric fusion protein. The immunogenic composition may be used to produce an immune response, for example, for treating or preventing an RSV infection. The immunogenic composition can be used in a **vaccine** composition, for example, as a part of a prophylactic and/or therapeutic **vaccine**.

11. WO/2026/193723 USE OF CHIRAL POLYPEPTIDE **VACCINE** IN DELAYING AGING

WO - 24.09.2026

Clasificación Internacional A61K 39/385Nº de solicitud PCT/CN2025/083346Solicitante LI, MeijunInventor/a LI, Meijun

The present invention provides a chiral **vaccine** for delaying aging, comprising a d-type polypeptide assembly and a **vaccine** adjuvant. The d-type polypeptide assembly is assembled from a d-type polypeptide. The d-type polypeptide is a (d)-TI polypeptide or a (d)-TI truncated form or a (d)-Tx polypeptide, and at least one chiral amino acid in the polypeptide is a D-type amino acid.

12. WO/2026/197674 REPLICATION-DEFICIENT SARS-COV-2 **VACCINE** STRAIN COMPRISING MUTATION IN N GENE AND USES THEREOF

WO - 24.09.2026

Clasificación Internacional C12N 7/00Nº de solicitud PCT/KR2026/003884Solicitante INDUSTRIAL COOPERATION FOUNDATION JEONBUK NATIONAL UNIVERSITYInventor/a MYOUNG, Jinjong

The present invention relates to a replication-deficient SARS-CoV-2 **vaccine** strain comprising a mutation in the *N* gene and uses thereof. More specifically, the present invention relates to a SARS-CoV-2 **vaccine** strain having five stop codons inserted into the *N* (nucleocapsid) gene of SARS-CoV-2, such that replication is impossible in cells in which the *N* gene is not trans-complemented, and uses thereof.

13. WO/2026/194080 PERTUSSIS MRNA **VACCINE**

WO - 24.09.2026

Clasificación Internacional A61K 39/10Nº de solicitud PCT/CN2025/100929 Solicitante WUHAN INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD Inventor/a MA, Lin

Provided is a pertussis mRNA **vaccine**. The present invention belongs to the technical field of biology. Antigens of the pertussis mRNA **vaccine** include pertussis toxin and filamentous hemagglutinin. Gene sequences of pertussis toxin include gS1 and gC180. The amino acid sequences corresponding to gS1 and gC180 comprise a mutation of arginine to lysine at position 9 and a mutation of glutamic acid to glycine at position 129, and a signal peptide of a human Igk light chain is added upstream of the amino acid sequences thereof in place of a natural bacterial signal peptide. Gene sequences of filamentous hemagglutinin include FHA456, FHA373, and FHA233. Optimizing gene sequences encoding the antigens gS1, gC180, FHA456, FHA373, and FHA233 can efficiently induce the body to produce an immune response.

14. 4808595 CORONAVIRUS-IMPFSTOFF

EP - 23.09.2026

Clasificación Internacional A61K 39/215Nº de solicitud 24827979 Solicitante BIONTECH SE Inventor/a GÜLER ALPTEKIN

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., **vaccine** RNA encoding **vaccine** antigen.

15. 20260286395 ANTI-CANCER VACCINES AND RELATED THERAPY

US - 24.09.2026

Clasificación Internacional C12N 15/86Nº de solicitud 19702550 Solicitante The Institute of Cancer Research: Royal Cancer Hospital Inventor/a Stephen Pettitt

The present invention provides an anti-cancer **vaccine** comprising: (i) at least one peptide comprising the amino acid sequence of a neoantigen encoded by a mutant homologous recombination (HR) DNA repair gene selected from the group: BRCA1, BRCA2, PALB2, CDK12, RAD51B, RAD51C and RAD51D, wherein the mutant gene comprises a reversion mutation; and/or (ii) at least one polynucleotide encoding the at least one peptide of (i). Also provided are engineered T cells that recognise said neoantigen. Related methods and medical uses of the **vaccine** and/or engineered T cell are provided, including for the treatment of cancers, such as homologous recombination (HR) deficient cancers that acquire PARP inhibitor resistance or platinum

resistance by development of reversion mutations in an HR DNA repair gene selected from the group: BRCA1, BRCA2, PALB2, CDK12, RAD51B, RAD51C and RAD51D.

16. WO/2026/198531A CANCER **VACCINE** FOR CANCER IMMUNOTHERAPY

WO - 24.09.2026

Clasificación Internacional C07K 14/47Nº de solicitud PCT/US2026/019532Solicitante TECLISON, INC.Inventor/a LEE, Ruey-min

The present disclosure provides a method for identifying a tumor specific small peptide that binds specifically to a CDR of an anti-tumor reactive T cell receptor (TCR) isolated from effective anti-tumor T cells and for identifying small peptides that bind specifically to the TCR. It further provides a tumor **vaccine** comprising an immunogenic amount of the identified tumor-specific neoantigen and formulations comprising a population of lipid nanoparticles (LNP) comprising a nucleic acid payload that encodes the tumor-specific antigen.

17. 20260284173RECOMBINANT EXPRESSION VECTOR FOR PRODUCTION OF VIRUS-LIKE PARTICLE-BASED MULTIVALENT NOROVIRUS **VACCINE** AND MANUFACTURING METHOD THEREFOR

US - 24.09.2026

Clasificación Internacional A61K 39/12Nº de solicitud 19474202Solicitante INTHERA INC.Inventor/a Deog Young CHOI

The present invention provides a fusion protein for promoting soluble expression of a norovirus antigen, and an expression vector thereof. More specifically, the present invention provides combinations of various genotypes of norovirus antigen proteins and RID mutants, in which the most efficient folding occurs when a norovirus antigen is used as a target protein to form a recombinant fusion protein, the yield of soluble expression of a fusion protein produced is improved, and the assembly efficacy and homogeneity of norovirus VLPs can be enhanced. Also, the present invention provides a method for rapidly mass-producing various other genotypes of norovirus VLPs, as well as GII.4, in *E. coli* by using mutant RID, thus enabling the development of a VLP-based multivalent **vaccine** comprising more genotypes.

18. 20260284167LIPOSOMAL FORMULATION FOR TREATMENT OF VISCERAL LEISHMANIASIS

US - 24.09.2026

Clasificación Internacional A61K 39/008Nº de solicitud 19476508Solicitante Council of Scientific & Industrial ResearchInventor/a Nahid ALI

Antigens from multiple sources is a promising strategy to effectively stimulate all immuno-phenotypic sections of a diverse population. Therefore, combination of multiple protective antigens is a rationale strategy to boost immunogenicity of the **vaccine** designed for immunization in heterogeneous population as well as to use in effective diagnosis in all endemic areas. The strategy to combine antigens is to construct a fusion chimeric multivalent antigen. The present invention relates to the diagnostic and **vaccine** potential of a recombinant multiantigenic T cell epitope enriched fusion protein comprising of three *Leishmania donovani* proteins, glycoprotein 63 (GP63), elongation factor 1 α (EF1- α) and cysteine protease C (CPC) against visceral leishmaniasis. The said invention in particular relates to designing, cloning and purification of a novel T cell enriched multiantigenic recombinant protein for detection of *Leishmania* infection in the form of antigen-specific antibodies in the biological samples such as serum and urine.

19. 20260284184 BIODEGRADABLE SCAFFOLDS FOR ENHANCING **VACCINE** EFFICACY

US - 24.09.2026

Clasificación Internacional A61K 39/385Nº de solicitud 19474126 Solicitante The Regents of the University of California Inventor/a Nisarg Shah

Scaffolds and materials which provide for sustained release of **vaccine** components upon delivery to a subject, thus resulting enhanced immune response compared to bolus vaccination strategies.

20. 20260287237 COLD STORAGE DEVICE

US - 24.09.2026

Clasificación Internacional F25D 3/08Nº de solicitud 19476686 Solicitante B MEDICAL SYSTEMS S.À.R.L. Inventor/a Simone BRUNO

An RFID enabled cold storage device, notably a **vaccine** storage device, has a cold storage compartment separated from an ice lining by a thermal barrier. The thermal barrier comprises a layer of thermal insulation material and a planar temperature distributing metal sheet, with the planar temperature distributing metal sheet providing an RFID antenna.

21. WO/2026/198408 METHODS OF TREATING A HEPATITIS B VIRUS INFECTION

WO - 24.09.2026

Clasificación Internacional A61K 31/00Nº de solicitud PCT/US2026/019312 Solicitante VIRION THERAPEUTICS, LLC Inventor/a CURRIE, Sue L.

Provided herein are methods of treating a hepatitis B infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of: a **vaccine** comprising a nucleic acid molecule that comprises a nucleotide sequence encoding an HBV polymerase N-terminal domain comprising the amino acid sequence of SEQ ID NO: 178 or an immunogenic fragment thereof, a nucleotide sequence encoding an HBV polymerase C-terminal domain comprising the amino acid sequence of SEQ ID NO: 179 or an immunogenic fragment thereof, and a nucleotide sequence encoding an HBV Core protein comprising the amino acid sequence of SEQ ID NO: 180 or an immunogenic fragment thereof; a hepatitis B virus-targeting siRNA; and an anti-Hepatitis B Surface Antigen (HBsAg) antibody; thereby treating the hepatitis B virus infection.

22. 20260284178 **VACCINE** WITH REDUCED ANTI-VECTOR ANTIGENICITY

US - 24.09.2026

Clasificación Internacional A61K 39/215Nº de solicitud 18868571 Solicitante MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. Inventor/a Reinhard FASSLER

The present invention relates to a recombinant replication-deficient or replication competent negative-strand RNA virus, (i) capable of displaying a heterologous antigen on the surface, and thus capable of inducing mucosal immunity in host, (ii) after entering a host cell, producing a heterologous antigen, thereby improving immune response of the host to the antigen, and (iii) having a reduced anti-vector antigenicity in comparison to the wildtype vector, thus reducing an immune response of the host to the vector.

23. WO/2026/197836 SELF-CIRCULARIZING RNA CONSTRUCT FOR HIGH-EFFICIENCY CIRCULAR RNA PRODUCTION

WO - 24.09.2026

Clasificación Internacional C12N 15/113Nº de solicitud PCT/KR2026/004499 Solicitante RZNOMICS INC. Inventor/a LEE, Seong Wook

The present invention provides a self-circularizing RNA construct and the like engineered to have improved self-circularization efficiency and/or enhanced ability to suppress impurity formation. The self-circularizing RNA construct of the present invention can be universally used for various GOIs, and is expected to be used, for the purpose of producing high-efficiency circular RNA, in various bio-industry fields such as **vaccine** development, gene therapeutics, and protein expression systems.

24. 4810613 MRNA-IMPfstoff gegen Herpes Zoster und Herstellungsverfahren dafür

EP - 23.09.2026

Clasificación Internacional C12N 15/62Nº de solicitud 24890645 Solicitante CSPC MEGALITH BIOPHARMACEUTICAL CO LTD Inventor/a FAN CHAO

25. 20260284181A A VIRAL VECTOR AND A **VACCINE** COMPOSITION COMPRISING THE VECTOR

US - 24.09.2026

Clasificación Internacional A61K 39/215Nº de solicitud 19479370 Solicitante Rokote Laboratories Finland Oy Inventor/a Kalle Saksela

The present invention provides a viral vector comprising, at an insertion site in the viral genome, a nucleic acid sequence encoding a modified extracellular domain of the SARS-CoV-2 spike protein, wherein said modified extracellular domain comprises an N-terminal signal peptide causing the spike protein to enter a secretory system in a host cell, wherein said modified extracellular domain comprises a C-terminal deletion of at least of heptad repeat 2 (HR2), transmembrane segment (TM) and cytoplasmic tail (CT) of the spike protein. The present invention also provides a vaccination composition comprising said viral vector.

26. WO/2026/198951 IONIZABLE LIPIDS AND LIPOSOMAL NANOPARTICLE COMPOSITIONS

WO - 24.09.2026

Clasificación Internacional C07D 317/28Nº de solicitud PCT/US2026/020236 Solicitante AKAGERA MEDICINES, INC. Inventor/a DRUMMOND, Daryl C.

Aspects of the present disclosure provide for improved compositions of bio-reducible and/or hydrolysable ionizable lipid compounds, useful in the preparation of lipid nanoparticles (LNP) for the delivery of therapeutic nucleic acids and other compounds to cells. Anionic phospholipids, including a phosphatidyl-L-serine (PS) or a phosphatidylglycerol (PG) can be included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. In some examples, the LNP compositions are **vaccine** compositions comprising mRNA encapsulated in lipid nanoparticles formed from an ionizable cationic lipid compound, cholesterol, an anionic phospholipid and a PEG conjugated lipid.

27. 20260286302 METHODS FOR PRODUCING A SUPER CENTRAL MEMORY CD8 T CELL SUBTYPE BY POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITION AND USES THEREOF

US - 24.09.2026

Clasificación Internacional C12N 5/0783Nº de solicitud 19473713 Solicitante Georgetown University Inventor/a Samir N. Khleif

A unique CD8 T cell central memory subtype obtained by treatment of CD8 T cells with a poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is described. These cells, referred to as super-central memory CD8 T cells (T_{CM}^{sup}) or PARPi-induced memory T cells, are significantly more efficient for cancer therapy than traditional central memory T cells (T_{CM}) generated by tumor antigens. Methods of using the T_{CM}^{sup} cells for enhancing cancer immunotherapy, enhancing vaccine-induced immunity, and treating cancer are described.

28. 20260286356 NUCLEIC ACID VACCINE FOR ACTIVATING NKG2C+ NATURAL KILLER CELLS

US - 24.09.2026

Clasificación Internacional C12N 15/113Nº de solicitud 19476061 Solicitante Charité-Universitätsmedizin Berlin Inventor/a Chiara Romagnani

A nucleic acid molecule including: (a) a sequence encoding a human cytomegalovirus (HCMV) UL40 signal peptide, or sequence variant thereof, and (b) an endoplasmic reticulum (ER)-targeting sequence. In a preferred embodiment the nucleic acid molecule further includes a stability inducing motif at its 3'-end. Also disclosed is a pharmaceutical composition including the nucleic acid molecule and a method of treating and/or reducing the risk of a medical condition associated with pathogenic cells expressing HLA-E, including administering a therapeutically effective amount of the nucleic acid molecule to a patient.

29. 4808594 TREHALOSE-IMPfstoff-Formulierung

EP - 23.09.2026

Clasificación Internacional A61K 39/12Nº de solicitud 24822004 Solicitante SANOFI VACCINES US INC Inventor/a LI QINGLIAN

Stable liquid, lyophilized, and frozen formulations are provided for live-attenuated and/or vector-based vaccines.

30. 20260285826 IONIZABLE LIPIDS AND LIPOSOMAL NANOPARTICLE COMPOSITIONS

US - 24.09.2026

Clasificación Internacional C07D 317/30Nº de solicitud 19636486 Solicitante Akagera Medicines, Inc. Inventor/a Daryl C. Drummond

Aspects of the present disclosure provide for improved compositions of bio-reducible and/or hydrolysable ionizable lipid compounds, useful in the preparation of lipid nanoparticles (LNP) for the delivery of therapeutic nucleic acids and other compounds to cells. Anionic phospholipids, including a phosphatidyl-L-serine (PS) or a phosphatidylglycerol (PG) can be included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. In some examples, the LNP compositions are vaccine compositions comprising mRNA encapsulated in lipid nanoparticles formed from an ionizable cationic lipid compound, cholesterol, an anionic phospholipid and a PEG conjugated lipid.

31. 4810957VERFAHREN ZUR BESTIMMUNG DES HEXOSAMINGEHALTS IN PNEUMOKOKKEN-POLYSACCHARIDPROBENLÖSUNG

EP - 23.09.2026

Clasificación Internacional G01N 33/50Nº de solicitud 24891712Solicitante SK BIOSCIENCE CO LTDInventor/a LEE HYE WON

The present invention relates to a method for determining the content of hexosamine in a pneumococcal polysaccharide sample solution. In quantitatively evaluating whether the hexosamine content of a produced pneumococcal polysaccharide undiluted solution sample is suitable for use in a vaccine, the method according to one aspect provides more accurate validation compared to the hexosamine content test method specified in the European Pharmacopoeia, and thus can be effectively utilized for quality control of pneumococcal polysaccharide vaccines or polysaccharide-protein conjugate vaccines containing hexosamine.

32. 20260284163PEPTIDE-BASED VACCINES AND METHODS FOR TREATMENT

US - 24.09.2026

Clasificación Internacional A61K 39/00Nº de solicitud 19358192Solicitante The Johns Hopkins UniversityInventor/a Efrosini Kokkoli

Provided are, inter alia, immunogenic and vaccine compositions including a lipid vesicle, a first nucleic acid; and a peptide, and methods of treating or preventing pancreatic cancer using the compositions.

33. 20260284195IONIZABLE LIPIDS AND LIPOSOMAL NANOPARTICLE COMPOSITIONS

US - 24.09.2026

Clasificación Internacional A61K 47/22Nº de solicitud 19575567Solicitante Akagera Medicines, Inc.Inventor/a Daryl C. Drummond

Aspects of the present disclosure provide for improved compositions of bioreducible and/or hydrolysable ionizable lipid compounds, useful in the preparation of lipid nanoparticles (LNP) for the delivery of therapeutic nucleic acids and other compounds to cells. Anionic phospholipids, including a phosphatidyl-L-serine (PS) or a phosphatidylglycerol (PG) can be included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. In some examples, the LNP compositions are vaccine compositions comprising mRNA encapsulated in lipid nanoparticles formed from an ionizable cationic lipid compound, cholesterol, an anionic phospholipid and a PEG conjugated lipid.

34. 20260283973IONIZABLE LIPIDS AND LIPOSOMAL NANOPARTICLE COMPOSITIONS

US - 24.09.2026

Clasificación Internacional A61K 9/51Nº de solicitud 19573533Solicitante Akagera Medicines, Inc.Inventor/a Daryl C. Drummond

Aspects of the present disclosure provide for improved compositions of bioreducible and/or hydrolysable ionizable lipid compounds, useful in the preparation of lipid nanoparticles (LNP) for the delivery of therapeutic nucleic acids and other compounds to cells. Anionic phospholipids, including a phosphatidyl-L-serine (PS) or a phosphatidylglycerol (PG) can be included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. In some examples, the LNP compositions are vaccine compositions comprising

mRNA encapsulated in lipid nanoparticles formed from an ionizable cationic lipid compound, cholesterol, an anionic phospholipid and a PEG conjugated lipid.

35. WO/2026/193684 METHOD FOR PREPARING SUSPENSION-ADAPTED CHICKEN EMBRYO FIBROBLASTS, AQP1 MUTANT DF-1 CELL LINE AND USE THEREOF

WO - 24.09.2026

Clasificación Internacional C12N 5/10Nº de solicitud PCT/CN2025/083119 Solicitante SHANDONG BINZHOU ANIMAL SCIENCE AND VETERINARY MEDICINE ACADEMY Inventor/a ZHAO, Xiubao

The present invention relates to the technical fields of cell preparation, virus proliferation and virus vaccines, and provides a method for preparing suspension-adapted chicken embryo fibroblasts, an AQP1 mutant DF-1 cell line and a use thereof. In the present invention, first and second transmembrane spacer sequences in an AQP1 gene of DF-1 cells are knocked out by means of gene editing, thereby changing the function of an AQP1 protein. The obtained AQP1 mutant cells exhibit improved suspension adaptability, stable genetic traits and increased viral yield, and can be applied to the production of poultry viral vaccines or propolis inactivated vaccines, replacing conventional cell vaccine production processes, and greatly improving production efficiency.

36. WO/2026/198949 IONIZABLE LIPIDS AND LIPOSOMAL NANOPARTICLE COMPOSITIONS

WO - 24.09.2026

Clasificación Internacional A61K 39/00Nº de solicitud PCT/US2026/020233 Solicitante AKAGERA MEDICINES, INC. Inventor/a DRUMMOND, Daryl C.

Aspects of the present disclosure provide for improved compositions of bio reducible and/or hydrolysable ionizable lipid compounds, useful in the preparation of lipid nanoparticles (LNP) for the delivery of therapeutic nucleic acids and other compounds to cells. Anionic phospholipids, including a phosphatidyl-L-serine (PS) or a phosphatidylglycerol (PG) can be included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. In some examples, the LNP compositions are vaccine compositions comprising mRNA encapsulated in lipid nanoparticles formed from an ionizable cationic lipid compound, cholesterol, an anionic phospholipid and a PEG conjugated lipid.

37. 20260284371 METHOD AND APPARATUS FOR EPIDERMAL DELIVERY OF POWDERED MEDICAMENTS

US - 24.09.2026

Clasificación Internacional A61M 37/00Nº de solicitud 19687980 Solicitante PARTICLE VACCINE CANADA LTD. Inventor/a Christopher RODRIGUEZ

Apparatus for transdermal delivery of a powdered agent to a patient, the apparatus comprising a fluid source comprising a fluid; a nozzle extending distally from the fluid source, the nozzle comprising a proximal end, a distal end and a lumen extending from the proximal end to the distal end; a blister containing a powdered agent disposed within the lumen of the nozzle; and an actuation element for releasing the fluid from the fluid source, wherein the actuation element causes the released fluid to be propelled through the blister with sufficient pressure to entrain the powdered agent into the released fluid and move the entrained powdered agent through the lumen of the nozzle and out the distal end of the nozzle.

38. 4810617 IN-VITRO-RNA-CYCLISIERUNGS- UND ROLLING-CIRCLE-TRANSLATIONSVERFAHREN AUF BASIS VON GRUPPE-I-INTRON UND VERWENDUNG

EP - 23.09.2026

Clasificación Internacional C12N 15/85Nº de solicitud 24890352 Solicitante UNIV FUDAN Inventor/a QU LIANG

A ribonucleic acid (RNA) in-vitro cyclization and rolling circle translation (RCT) method based on a group I intron, and a use. A specific non-complementary region of the group I intron is split to obtain an RNA construct, the preparation of a "scarless" circular RNA is implemented by means of the principle of ribozyme self-splicing, and the method is generalized to other group I introns. By optimizing a split structure, in the absence of homology arms, efficient cyclization can be achieved without the need for additional GTP catalysis. Additionally, the components of the RNA construct are optimized, thereby further improving the cyclization efficiency. An RCT technology platform based on a CITE sequence is established, thereby greatly improving the expression level of a protein or polypeptide. It has been verified that the cyclization and RCT method shows potential in **vaccine** and CAR treatment, and is expected to be used in the clinical treatment of various diseases.

39. 4810522 FUSIONSPROTEIN UND VERWENDUNG DAVON

EP - 23.09.2026

Clasificación Internacional C07K 19/00Nº de solicitud 24890649 Solicitante WECARELIFE BIOTECH CO LTD Inventor/a CAO ZHEN

The invention relates to the technical field of biology, in particular to a fusion protein and a use thereof. A polypeptide fragment for targeted identification of a monomolecular phospholipid membrane and a polypeptide fragment for targeted identification of a tissue or cell are connected, and the formed fusion protein can specifically bound to the surface of a fat body in a non-covalent mode, such that accurate targeting of the fat body is achieved. The targeted fat body constructed by the fat body targeting peptide fragment can be widely used in fields of precise drug delivery, **vaccine** preparation etc., and is used for treating diseases such as cancer, infectious diseases and metabolic diseases. Lung tissues and breast cancer cells are used as targets, so that good targeting of the fat body is achieved.

40. 20260284172A BROADLY PROTECTIVE PROPHYLACTIC **VACCINE** AGAINST PSEUDOMONAS AERUGINOSA

US - 24.09.2026

Clasificación Internacional A61K 39/104Nº de solicitud 19377934 Solicitante UNIVERSITY OF KANSAS Inventor/a Wendy L. PICKING

Disclosed are compositions comprising a fusion polypeptide comprising i) a fusion of a needle tip protein or an antigenic fragment thereof and/or a translocator protein or an antigenic fragment thereof from a Type III secretion system (T3SS) of a Gram negative bacteria and ii) the A1 subunit of the labile toxin (LTA1) from enterotoxigenic *Escherichia coli* or cholera toxin. and methods of their use.

41. WO/2026/198956 MEASLES HEMAGGLUTININ AND FUSION MABS

WO - 24.09.2026

Clasificación Internacional C07K 16/08Nº de solicitud PCT/US2026/020242Solicitante LA JOLLA INSTITUTE FOR IMMUNOLOGYInventor/a SAPHIRE, Erica Ollmann

The present disclosure provides, among other things, antibodies or antigen binding antibody fragments thereof that bind to a MeV Fusion or Hemagglutinin protein or a fragment thereof, nucleic acids comprising a polynucleotide sequence encoding such antibodies or antibody fragments, vectors comprising such nucleic acids, engineered cells comprising such nucleic acids or vectors, and compositions comprising one or more antibodies or antibody fragments, nucleic acids, or vectors of the disclosure. The present disclosure also provides methods of treating a subject infected with MeV or reducing the likelihood of infection of a subject at risk of contracting MeV, **vaccine** formulations, methods of detecting infection with MeV, and kits comprising technologies of the present disclosure.

42.WO/2026/195656MODIFIED VERO CELL LINE FOR VIRUS PROPAGATION

WO - 24.09.2026

Clasificación Internacional C12N 7/00Nº de solicitud PCT/EP2026/057468Solicitante NUCELL GMBHInventor/a KROKHIN, Artem

The present invention relates to a modified Vero cell or progeny thereof comprising a decreased intracellular pH, a reduced expression of the DDX60L gene and an increased expression of one or more of genes ATP6V1C2, SLC16A4, SLC22A31 and SLC34A2 compared to a parental, unmodified Vero cell. The modified Vero cell is deposited under accession number DSM ACC3381 at the DSMZ German Collection of Microorganisms and Cell Cultures GmbH. The invention also relates to a modified Vero cell line comprising said modified Vero cell, and methods for generating and maintaining said modified Vero cell line. The invention further relates to the modified Vero cell propagating a virus, the use of the modified Vero cell or modified Vero cell line for producing a virus, a method for manufacturing a virus from the modified Vero cell line, and a method for manufacturing a viral **vaccine** from the modified Vero cell line.

43.4808590PEPTIDKONJUGATIMPFSTOFFZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON MORBUS ALZHEIMER

EP - 23.09.2026

Clasificación Internacional A61K 39/00Nº de solicitud 24820499Solicitante MERCK SHARP & DOHME LLCInventor/a HSU YEN-PANG

The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of A β in the brain of a patient, such as Alzheimer's Disease. Such methods entail administering a pharmaceutical composition comprising an immunogenic fragment of A β capable of inducing a beneficial immune response in the form of antibodies to A β . The immunogenic fragments comprise linear or multivalent peptides of A β . Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.

44.WO/2026/197837SELF-CIRCULARIZED RNA CONSTRUCT FOR HIGH-EFFICIENCY CIRCULAR RNA PRODUCTION

WO - 24.09.2026

Clasificación Internacional C12N 15/113Nº de solicitud PCT/KR2026/004501 Solicitante RZNOMICS INC. Inventor/a LEE, Seong Wook

The present invention provides a self-circularized RNA construct that has, through engineering, improved self-circularization efficiency and/or impurity formation inhibitory efficacy. The self-circularized RNA construct of the present invention can be universally used for various GOIs, and is expected to be used in various fields of the biotechnology industry, such as **vaccine** development, gene therapeutics, and protein expression systems, for the purpose of producing high-efficiency circular RNA.

45. WO/2026/198437 THERAPEUTIC HUMAN PAPILLOMAVIRUS MRNA **VACCINE** AND ADJUVANT FOR SAME

WO - 24.09.2026

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2026/019360 Solicitante CORNER THERAPEUTICS, INC. Inventor/a CHOW, Jonathan

The present disclosure relates to isolated mRNA encoding human papillomavirus (HPV) oncoproteins and another early viral protein. The present disclosure also relates to compositions for expression of a cyclic GMP-AMP synthase and one or more HPV early proteins in cells of a mammalian subject. The compositions of the present disclosure are useful for stimulating an immune response against HPV.

46. 20260284176 HIV **VACCINE**

US - 24.09.2026

Clasificación Internacional A61K 39/21Nº de solicitud 19474552 Solicitante BioNTech SE Inventor/a Valentin LE DOUCE

The present invention concerns compositions comprising an RNA molecule, wherein the RNA molecule comprises an expression cassette encoding an immunogenic peptide, which peptide comprises at least two fragments, wherein each fragment comprises at least one epitope, wherein the epitope is derived from an amino acid sequence encoded by the human immunodeficiency virus (HIV) and medical preparations comprising such compositions. Furthermore, the invention concerns methods for preventing or treating HIV.

47. WO/2026/198569 INFLUENZA A VIRUS **VACCINE** AND METHODS OF USE THEREOF

WO - 24.09.2026

Clasificación Internacional C12N 15/86Nº de solicitud PCT/US2026/019590 Solicitante THOMAS JEFFERSON UNIVERSITY Inventor/a SCHNELL, Matthias Johannes

The present disclosure relates, in part, to nucleic acids encoding a recombinant virus comprising hemagglutinin (HA), or a portion thereof, and recombinant viruses and/or vectors comprising the same. In certain embodiments, the HA is highly pathogenic avian influenza hemagglutinin 5 (HPAI H5). The present disclosure further relates to vaccines comprising the nucleic acids, recombinant viruses, and/or vectors of the present disclosure, and methods of use thereof.

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búsqueda: *vaccine.ti. AND @PD>="20260923"<=20260930* 24 records

Document ID	Title	Inventor	Applicant Name
US 12746280 B2	Chagas disease vaccine antigens with improved stability and decreased aggregation	Zhan; Bin et al.	Baylor College of Medicine
US 12747265 B2	FOXM1-derived peptide, and vaccine including same	Yamashita; Sachiko et al.	OncoTherapy Science, Inc.
US 12746284 B2	Immune adjuvant and vaccine composition including the same	Lee; Minja et al.	REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY)
US 12746282 B2	Recombinant modified vaccinia virus (MVA) vaccine against coronavirus disease	Hausmann; Jürgen et al.	Bavarian Nordic A/S
US 12749556 B2	Selection of cancer mutations for generation of a personalized cancer vaccine	Nicosia; Alfredo et al.	NOUSCOM AG
US 12746283 B2	Dengue vaccine unit dose and administration thereof	Wallace; Derek	Takeda Vaccines, Inc.
US 12747268 B2	High-potency SARS coronavirus 2 antigen and vaccine composition comprising same	Kim; Seong Jun et al.	KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
US 20260286434 A1	Biomarker composition for predicting efficacy of tuberculosis vaccine comprising CCL5 and use thereof	HA; Sang Jun et al.	INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

US 20260286438 A1	Biomarker composition for predicting efficacy of tuberculosis vaccine comprising NKg7 and use thereof	HA; Sang Jun et al.	INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
US 20260284173 A1	RECOMBINANT EXPRESSION VECTOR FOR PRODUCTION OF VIRUS-LIKE PARTICLE-BASED MULTIVALENT NOROVIRUS VACCINE AND MANUFACTURING METHOD THEREFOR	CHOI; Deog Young et al.	INTHERA INC.
US 20260284178 A1	VACCINE WITH REDUCED ANTI-VECTOR ANTIGENICITY	FASSLER; Reinhard et al.	MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
US 20260284179 A1	CORONAVIRUS VACCINES INDUCING BROAD IMMUNITY AGAINST VARIANTS	HEENEY; Jonathan Luke et al.	DIOSynVax Ltd, Cambridge Enterprise Limited
US 20260284181 A1	A viral vector and a vaccine composition comprising the vector	Saksela; Kalle et al.	Rokote Laboratories Finland Oy
US 20260286356 A1	NUCLEIC ACID VACCINE FOR ACTIVATING NKG2C+ NATURAL KILLER CELLS	Romagnani; Chiara et al.	Charité-Universitätsmedizin Berlin, Deutsches Rheuma-Forschungszentrum Berlin
US 20260285920 A1	HORN FLY VACCINE COMPOSITIONS AND METHODS OF MAKING SAME	Van Kampen; Kent R. et al.	TNG Pharmaceuticals, Inc.
US 20260286395 A1	ANTI-CANCER VACCINES AND RELATED THERAPY	Pettitt; Stephen et al.	The Institute of Cancer Research: Royal Cancer Hospital

US 20260284172 A1	A BROADLY PROTECTIVE PROPHYLACTIC VACCINE AGAINST PSEUDOMONAS AERUGINOSA	PICKING; Wendy L. et al.	UNIVERSITY OF KANSAS, UNIVERSITY OF MARYLAND, BALTIMORE
US 20260284177 A1	HETEROLOGOUS PRIME BOOST VACCINE COMPOSITIONS AND METHODS OF USE	Samayoa; Phillip et al.	Generation Bio Co.
US 20260284175 A1	HIV IMMUNOGENIC POLYPEPTIDES AND VACCINES AND USES THEREOF	Bekerman; Elena et al.	Gilead Sciences, Inc.
US 20260284174 A1	INFLUENZA VIRUS VACCINES	DORMITZER; Philip R. et al.	GLAXOSMITHKLINE BIOLOGICALS SA
US 20260284176 A1	HIV VACCINE	LE DOUCE; Valentin et al.	BioNTech SE, THE GENERAL HOSPITAL CORPORATION
US 20260284184 A1	BIODEGRADABLE SCAFFOLDS FOR ENHANCING VACCINE EFFICACY	Shah; Nisarg et al.	The Regents of the University of California
US 20260284163 A1	PEPTIDE-BASED VACCINES AND METHODS FOR TREATMENT	Kokkoli; Efrosini et al.	The Johns Hopkins University
US 20260284187 A1	POLYSACCHARIDE ADJUVANTS FOR USE IN PROTEIN-BASED OR RNA-BASED VACCINES	Zanoni; Ivan et al.	The Children's Medical Center Corporation, The Brigham and Women's Hospital, Inc.

NOTA ACLARATORIA: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez	aramos@finlay.edu.cu
Randelys Molina Castro	rmolina@finlay.edu.cu
Claudia Camejo Salas	ccamejo@finlay.edu.cu
Yamira Puig Fernández	yamipuig@finlay.edu.cu

